0000950170-24-038107 | 20-F | XBRL Viewer

$ 14,778

$ 14,798

$ 20

3,000

Disclosure of detailed information about intangible assets [line items]

14,757

14,778

14,798

Cost [Member]

18,875

11,375

Addition

7,500

Amortisation and Impairment [Member]

18,875

Disclosure of detailed information about intangible assets [line items]

(4,097)

(4,077)

(1,057)

(21)

(20)

(3,000)

Patent Rights (available for use) [Member]

(4,118)

(4,097)

(4,077)

Disclosure of detailed information about intangible assets [line items]

^[1]

278

298

Patent Rights (available for use) [Member] | Cost [Member]

^[1]

257

278

298

Disclosure of detailed information about intangible assets [line items]

^[1]

375

Patent Rights (available for use) [Member] | Amortisation and Impairment [Member]

^[1]

375

Disclosure of detailed information about intangible assets [line items]

^[1]

(97)

(77)

(57)

^[1]

(21)

(20)

^[1]

Patent Rights (not yet available for use) [Member]

^[1]

(118)

(97)

(77)

Disclosure of detailed information about intangible assets [line items]

^[2]

14,500

Patent Rights (not yet available for use) [Member] | Cost [Member]

^[2]

14,500

Disclosure of detailed information about intangible assets [line items]

^[2]

18,500

11,000

Addition

^[2]

7,500

Patent Rights (not yet available for use) [Member] | Amortisation and Impairment [Member]

^[2]

18,500

Disclosure of detailed information about intangible assets [line items]

^[2]

(4,000)

(1,000)

^[2]

^[2]

(3,000)

^[2]

$ (4,000)

[1]

The patent rights grant the Group the right to use certain scientific data for research and manufacture of pipelines, namely APL-501, APL-502 and APL-509.

[2]

These patent rights are not yet available for use by the Group as the Group is still undergoing pre-clinical study application or clinical trials on the relevant drugs in designated territories under the patent rights and has yet to obtain regulatory approval for the new drug to be launched to the market. The patent rights are tested for impairment annually and whenever there is an indication that they may be impaired. Amortization will commence when the patent rights are available for use (i.e. when they are ready for commercialization and have obtained the regulatory new drug application approval in the designated territories) by the Group. During the years ended December 31, 2021, 2022 and 2023, patent rights with carrying amount of $3,000, nil, and nil were impaired, respectively. For these patent rights, as they were acquired for combination trial of an existing drug candidate, which was subsequently replaced by another formulation, or acquired for self-development that the Group cannot proceed further research due to the failure in providing drug supplies by the original vendor according to the agreement. Accordingly, the Group has fully impaired the patent rights with reference to their respective recoverable amounts determined on value in use calculations.

Loss Per Share - Disclosure of Basic and Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			12 Months Ended
	Mar. 29, 2023	Mar. 28, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [line items]
Loss for the year attributable to owners of the Company for the purpose of calculating basic and diluted loss per share			$ (172,601)	$ (240,811)	$ (94,797)
Weighted average number of ordinary shares used in calculating basic earnings per share	404,186		74,411	28,528	28,107
Weighted average number of ordinary shares used in calculating diluted earnings per share	390,944		74,411	28,528	28,107
Total basic earnings (loss) per share		$ (0.23)	$ (2.32)	$ (8.44)	$ (3.37)
Total diluted earnings (loss) per share		$ (0.62)	$ (2.32)	$ (8.44)	$ (3.37)

Deferred tax assets and liabilities [abstract]

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 18
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2023-01-01
-Paragraph 24
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 17
-IssueDate 2023-01-01
-Paragraph 113
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 81A
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2023-03-23

+ Details

Share-Based Payment Transaction - Summary of Restricted stock (Details) - Two Thousand Twenty Three Plan [Member] - Restricted share units [member]	12 Months Ended
	Dec. 31, 2023 shares $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Outstanding at January 1	0
Granted	207,945
Outstanding at December 31,	207,945
Exercisable	0
Weighted average exercise price at January 1 \| $ / shares	$ 0
Weighted average exercise price, granted \| $ / shares	5.41
Weighted average exercise price December 31 \| $ / shares	$ 5.41

Deferred Taxation

12 Months Ended

Dec. 31, 2023

Deferred Taxation

18.

DEFERRED TAXATION

For the purpose of presentation in the consolidated financial statements, the deferred tax assets and liabilities have been offset.

The major deferred tax assets (liabilities) recognized and movements thereon during the years ended December 31, 2021, 2022 and 2023 are as follows:


	Accelerated tax depreciation			Accrual			Total
As of January 1, 2021	$	(46	)	$	46		$	—
Credit (charge) to profit or loss (Note 10)		14			(14	)		—
As of December 31, 2021		(32	)		32			—
Credit (charge) to profit or loss (Note 10)		(19	)		19			—
As of December 31, 2022		(51	)		51			—
(Charge) credit to profit or loss (Note 10)		40			(40	)		—
As of December 31, 2023	$	(11	)	$	11		$	—

The Group had unused tax losses of $62,866 available for offset against future profits as of December 31, 2022. The Group had unused tax losses, temporary differences and unused tax credits of $97,607, $17,221 and $7,462, respectively, as of December 31, 2023. No deferred tax asset has been recognized due to the unpredictability of future profit streams. As of December 31, 2022 and 2023, the unrecognized tax losses and temporary differences will be carried forward and expire in years as follows:


	As of December 31,
	2022		2023
Unused tax losses
2024	$	2,364	$	2,319
2025		4,634		4,973
2026		7,025		10,144
2027		15,757		9,176
2028		—		9,571
Indefinite		33,086		61,424
Total unused tax losses	$	62,866	$	97,607
Tax effected deductible temporary differences
Indefinite		15,506		17,221
	$	15,506	$	17,221

As of December 31, 2023 the unused credits will be carried forward and expire in years as follows:


Unused tax credits
2038	$	62
2039		229
2040		1,320
2041		1,800
2042		2,589
2043		1,462
Total unused tax credits	$	7,462

Management has estimated the expected outcome of the disputes by using the expected value method to determine the provisions for uncertain tax treatment. The Group reported uncertain tax treatment of $2,190 as of December 31, 2023, netted in the deferred tax assets, that are not recognized in the financial statements.

Revenue and Segment Information - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Entitys Revenue And Reportable Segments [Line Items]
Revenue	$ 0	$ 0	$ 0

Disclosure of Summary of Significant Accounting Policies [Abstract]

The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 28
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 23
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 32
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard
-URIDate 2023-03-23

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard
-URIDate 2023-03-23

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 33
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard
-URIDate 2023-03-23

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 34
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard
-URIDate 2023-03-23

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B10
-Subparagraph b
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 82
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard
-URIDate 2023-03-23

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 103
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard
-URIDate 2023-03-23

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 102
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard
-URIDate 2023-03-23

+ Details

Convertible Preferred Shares - Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares (Detail) - Series C Preferred Shares [Member] - Preferred Shares [Member]	Dec. 31, 2022 yr	Dec. 31, 2021 yr
Time to Liquidate [Member]
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items]
Significant unobservable input, liabilities	1.25	1.5
Risk-free rate [Member]
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items]
Significant unobservable input, liabilities	4.65	0.56
Expected volatility (note) [Member]
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items]
Significant unobservable input, liabilities	75	72.5
Dividend Yield [Member]
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items]
Significant unobservable input, liabilities	0	0
Possibility Under IPO Scenario [Member]
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items]
Significant unobservable input, liabilities	85	25
Possibility Under Liquidation Scenario [Member]
Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares [Line Items]
Significant unobservable input, liabilities	15	75

Material Accounting Policies

12 Months Ended

Dec. 31, 2023

Material Accounting Policies

MATERIAL ACCOUNTING POLICIES

The consolidated financial statements have been prepared in accordance with the following accounting policies set out below which conform with IFRSs issued by the IASB. For the purpose of preparation of the consolidated financial statements, information is considered material if such information is reasonably expected to influence decisions made by primary users.

The consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair value at the end of each reporting period, as explained in the accounting policies set out below.

Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in the financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2 Share-based Payments, leasing transactions that are within the scope of IFRS 16 Leases, and measurements that have some similarities to fair value but are not fair value, such as net realizable value in IAS 2 Inventories or value in use in IAS 36 Impairment of Assets.

For financial instruments which are transacted at fair value and a valuation technique that unobservable inputs are to be used to measure fair value in subsequent periods, the valuation technique is calibrated so that at initial recognition the results of the valuation technique equals the transaction price.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

•

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;

•

Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and

•

Level 3 inputs are unobservable inputs for the asset or liability.

The principal accounting policies are set out below.

Basis of consolidation

The consolidated financial statements incorporate the financial statements of Apollomics and entities controlled by Apollomics and its subsidiaries. Control is achieved when the Company:

•

has power over the investee;

•

is exposed, or has rights, to variable returns from its involvement with the investee; and

•

has the ability to use its power to affect its returns.

The Group reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

Consolidation of a subsidiary begins when the Group obtains control over the subsidiary and ceases when the Group loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statements of profit or loss and other comprehensive income from the date the Group gains control until the date when the Group ceases to control the subsidiary.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies in line with the Group’s accounting policies.

All intragroup assets, liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

Foreign currencies

In preparing the financial statements of each individual group entity, transactions in currencies other than the functional currency of that entity (foreign currencies) are recognized at the rates of exchanges prevailing on the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are recognized in profit or loss in the period in which they arise.

Government grants

Government grants are not recognized until there is reasonable assurance that the Group will comply with the conditions attaching to them and that the grants will be received.

Government grants related to income that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Group with no future related costs are recognized in profit or loss in the period in which they become receivable. Such grants are presented under “other income”.

Retirement benefits costs

Payments to defined contribution retirement benefit plans, including the defined contribution plan in the US, state-managed retirement benefit schemes in the People’s Republic of China (the “PRC”) are recognized as an expense when employees have rendered service entitling them to the contributions.

Short-term employee benefits

Short-term employee benefits are recognized at the undiscounted amount of the benefits expected to be paid as and when employees rendered the services. All short-term employee benefits are recognized as an expense unless another IFRS requires or permits the inclusion of the benefit in the cost of an asset.

A liability is recognized for benefits accruing to employees (such as wages, salaries and leave entitlement) after deducting any amount already paid.

Share-based payments

Equity-settled share-based payment transactions

Share options and restricted shares granted to employees and others providing similar services

Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date.

The fair value of the equity-settled share-based payments determined at the grant date without taking into consideration all non-market vesting conditions is expensed on a straight-line basis over the vesting period, based on the Group’s estimate of equity instruments that will eventually vest, with a corresponding increase in equity (share-based payment reserve). At the end of each reporting period, the Group revises its estimate of the number of equity instruments expected to vest based on assessment of all relevant non-market vesting conditions. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to the share-based payment reserve.

When share options are exercised or the restricted shares are vested, the amount previously recognized in share-based payment reserve will be transferred to other reserve. When the share options are forfeited after the vesting date or are still not exercised at the expiry date, the amount previously recognized in share-based payment reserve will be transferred to accumulated losses.

Taxation

Income taxation represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from ‘loss before taxation’ because of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of each reporting period.

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the consolidated financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized. Such deferred tax assets and liabilities are not recognized if the temporary difference arises from the initial recognition of assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognized for taxable temporary differences associated with investments in subsidiaries, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments are only recognized to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of each reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of each reporting period, to recover or settle the carrying amount of its assets and liabilities.

For the purposes of measuring deferred tax for leasing transactions in which the Group recognizes the right-of-use assets and the related lease liabilities, the Group first determines whether the tax deductions are attributable to the right-of-use assets or the lease liabilities.

For leasing transactions in which the tax deductions are attributable to the lease liabilities, the Group applies IAS 12 requirements to the leasing transaction as a whole. Temporary differences relating to right-of-use assets and lease liabilities are assessed on a net basis.

Excess of depreciation on right-of-use assets over the lease payments for the principal portion of lease liabilities resulting in net deductible temporary differences.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied to the same taxable entity by the same taxation authority.

Current and deferred tax are recognized in profit or loss.

Plant and equipment

Plant and equipment are stated at cost less subsequent accumulated depreciation and subsequent accumulated impairment losses, if any.

Depreciation is recognized so as to write off the cost of assets less their residual values over their estimated useful lives, using the straight-line method. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

An item of plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. Any gain or loss arising on the disposal or retirement of an item of plant and equipment is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss.

Leases

Definition of a lease

A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

The Group assesses whether a contract is or contains a lease based on the definition under IFRS 16 at inception, modification date or acquisition date, as appropriate. Such contract will not be reassessed unless the terms and conditions of the contract are subsequently changed.

The Group as a lessee

Allocation of consideration to components of a contract

For a contract that contains a lease component and one or more additional lease or non-lease components, the Group allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.

The Group applies practical expedient not to separate non-lease components from lease component, and instead account for the lease component and any associated non-lease components as a single lease component.

Short-term leases

The Group applies the short-term lease recognition exemption to leases of plant and equipment and laboratory premise, that have a lease term of 12 months or less from the commencement date and do not contain a purchase option. Lease payments on short-term leases is recognized as expense on a straight-line basis over the lease term.

Right-of-use assets

Except for short-term leases, the Group recognizes right-of-use assets at the commencement date of the lease (i.e. the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities.

The cost of right-of-use assets includes the amount of the initial measurement of the lease liability.

Right-of-use assets in which the Group is reasonably certain to obtain ownership of the underlying leased assets at the end of the lease term is depreciated from commencement date to the end of the useful life. Otherwise, right-of-use assets are depreciated on a straight-line basis over the shorter of its estimated useful life and the lease term.

The Group presents right-of-use assets as a separate line item on the consolidated statements of financial position.

Refundable rental deposits

Refundable rental deposits paid are accounted for under IFRS 9Financial Instruments and initially measured at fair value. Adjustments to fair value at initial recognition are considered as additional lease payments and included in the cost of right-of-use assets.

Lease liabilities

At the commencement date of a lease, the Group recognizes and measures the lease liability at the present value of lease payments that are unpaid at that date. In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable.

The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

The Group presents lease liabilities as a separate line item on the consolidated statements of financial position.

Intangible assets

Intangible assets acquired separately

Intangible assets with finite useful lives that are acquired separately are carried at costs less accumulated amortization and any accumulated impairment losses if any. Amortization for intangible assets with finite useful lives is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets not yet available for use that are acquired separately are carried at cost less any subsequent accumulated impairment losses.

Internally-generated intangible assets - research and development expenditure

Expenditure on research activities is recognized as an expense in the period in which it is incurred.

An internally generated intangible asset arising from development activities (or from the development phase of an internal project) is recognized if, and only if, all of the following have been demonstrated:

•

the technical feasibility of completing the intangible asset so that it will be available for use or sale;

•

the intention to complete the intangible asset and use or sell it;

•

the ability to use or sell the intangible asset;

•

how the intangible asset will generate probable future economic benefits;

•

the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and

•

the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognized for internally-generated intangible asset is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.

Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses (if any), on the same basis as intangible assets that are acquired separately.

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains and losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, are recognized in profit or loss when the asset is derecognized.

Impairment on plant and equipment, right-of-use assets and intangible assets

At the end of each reporting period, the management of the Company reviews the carrying amounts of plant and equipment, right-of-use assets and intangible assets with finite useful lives to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the relevant asset is estimated in order to determine the extent of the impairment loss, if any. Intangible assets not yet available for use are tested for impairment at least annually, and whenever there is an indication that they may be impaired.

The recoverable amount of plant and equipment, right-of-use assets and intangible assets is estimated individually. When it is not possible to estimate the recoverable amount of an asset individually, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

In testing a cash-generating unit for impairment, corporate assets are allocated to the relevant cash-generating unit when a reasonable and consistent basis of allocation can be established, or otherwise they are allocated to the smallest group of cash generating units for which a reasonable and consistent allocation basis can be established. The recoverable amount is determined for the cash-generating unit or group of cash-generating units to which the corporate asset belongs, and is compared with the carrying amount of the relevant cash-generating unit or group of cash-generating units.

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset (or cash-generating unit) for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or a cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. For corporate assets or portion of corporate assets which cannot be allocated on a reasonable and consistent basis to a cash-generating unit, the Group compares the carrying amount of a group of cash-generating units, including the carrying amounts of the corporate assets or portion of corporate assets allocated to that group of cash-generating units, with the recoverable amount of the group of cash-generating units. In allocating the impairment loss, the impairment loss is allocated first to reduce the carrying amount of any goodwill (if applicable) and then to the other assets on a pro-rata basis based on the carrying amount of each asset in the unit. The carrying amount of an asset is not reduced below the highest of its fair value less costs of disposal (if measurable), its value in use (if determinable) and zero. The amount of the impairment loss that would otherwise have been allocated to the asset is allocated pro rata to the other assets of the unit or a group of cash-generating units. An impairment loss is recognized immediately in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit or a group of cash-generating units) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or

cash-generating unit or a group of cash-generating units) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

Cash and cash equivalents

Cash and cash equivalents presented on the consolidated statements of financial position include:

(a) cash, which comprises of cash on hand and demand deposits; and

(b) cash equivalents, which comprises of short-term (generally with original maturity of three months or less), highly liquid investments that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather than for investment or other purposes.

For the purposes of the consolidated statements of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above.

Financial instruments

Financial assets and financial liabilities are recognized when a group entity becomes a party to the contractual provisions of the instrument. All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets or liabilities at FVTPL) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at FVTPL are recognized immediately in profit or loss.

The effective interest method is a method of calculating the amortized cost of a financial asset or financial liability and of allocating interest income and interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts and payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset or financial liability, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Financial assets

Classification and subsequent measurement of financial assets

Financial assets that meet the following conditions are subsequently measured at amortized cost:

•

the financial asset is held within a business model whose objective is to collect contractual cash flows; and

•

the contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

All other financial assets are subsequently measured at FVTPL.

(i)

Amortized cost and interest income

Interest income is recognized using the effective interest method for financial assets measured subsequently at amortized cost. Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset, except for financial assets that have subsequently become credit-impaired (see below). For financial assets that have subsequently become credit-impaired, interest income is recognized by applying the effective interest rate to the amortized cost of the financial asset from the next reporting period. If the credit risk on the credit-impaired financial instrument improves so that the financial asset is no longer credit-impaired, interest income is recognized by applying the effective interest rate to the gross carrying amount of the financial asset from the beginning of the reporting period following the determination that the asset is no longer credit impaired.

Interest income is recognized in profit or loss and is included in the “other income” line item.

(ii)

Financial assets at FVTPL

Financial assets of the Group that do not meet the criteria for being measured at amortized cost are measured at FVTPL.

Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any fair value gains or losses recognized in profit or loss. The net gain or loss recognized in profit or loss includes any interest earned on the financial asset and is presented as “fair value change of financial assets at FVTPL” line item.

Impairment of financial assets

The Group performs impairment assessment under expected credit loss (“ECL”) model on financial assets (including deposits, time deposits with original maturity over three months and cash and cash equivalents) which are subject to impairment under IFRS 9. The amount of ECL is updated at each reporting date to reflect changes in credit risk since initial recognition.

Lifetime ECL represents the ECL that will result from all possible default events over the expected life of the relevant instrument. In contrast,12-month ECL represents the portion of lifetime ECL that is expected to result from default events that are possible within 12 months after the reporting date. Assessments are done based on the Group’s historical credit loss experience, adjusted for factors that are specific to the debtors, general economic conditions and an assessment of both the current conditions at the reporting date as well as the forecast of future conditions.

For all financial instruments, the Group measures the loss allowance equal to12-month ECL, unless when there has been a significant increase in credit risk since initial recognition, the Group recognizes lifetime ECL. The assessment of whether lifetime ECL should be recognized is based on significant increases in the likelihood or risk of a default occurring since initial recognition.

(i)

Significant increase in credit risk

In assessing whether the credit risk on a financial instrument has increased significantly since initial recognition, the Group compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition. In making this assessment, the Group considers both quantitative and qualitative information that is reasonable and supportable, including historical experience and forward-looking information that is available without undue cost or effort.

Forward-looking information considered includes the future prospects of the industries in which the Group’s debtors operate, obtained from economic expert reports, financial analysts, governmental bodies, relevant think-tanks and other similar organizations, as well as consideration of various external sources of actual and forecast economic information that relate to the Group’s core operations.

In particular, the following information is taken into account when assessing whether credit risk has increased significantly:

•

an actual or expected significant deterioration in the financial instrument’s external (if available) or internal credit rating;

•

significant deterioration in external market indicators of credit risk for a particular financial instrument, e.g. a significant increase in the credit spread, the credit default swap prices for the debtor;

•

existing or forecast adverse changes in business, financial or economic conditions that are expected to cause a significant decrease in the debtor’s ability to meet its debt obligations;

•

an actual or expected significant deterioration in the operating results of the debtor; and

•

an actual or expected significant adverse change in the regulatory, economic, or technological environment of the debtor that results in a significant decrease in the debtor’s ability to meet its debt obligations.

Irrespective of the outcome of the above assessment, the Group presumes that the credit risk on a financial asset has increased significantly since initial recognition when contractual payments are more than 30 days past due, unless the Group has reasonable and supportable information that demonstrates otherwise.

Notwithstanding the foregoing, the Group assumes that the credit risk on a debt instrument has not increased significantly since initial recognition if the financial instrument is determined to have low credit risk at the reporting date. A financial instrument is determined to have low credit risk if i) the financial instrument has a low risk of default, ii) the borrower has a strong capacity to meet its contractual cash flow obligations in the near term and iii) adverse changes in economic and business conditions in the longer term may, but will not necessarily, reduce the ability of the borrower to fulfill its contractual cash flow obligations. The Group considers a debt instrument have low credit risk when it has an internal or external credit rating of “investment grade” as per globally understood definition.

The Group regularly monitors the effectiveness of the criteria used to identify whether there has been a significant increase in credit risk and revises them as appropriate to ensure that the criteria are capable of identifying significant increase in credit risk before the amount becomes past due.

(ii)

Definition of default

The Group considers the following as constituting an event of default for internal credit risk management purposes as historical experience indicates that receivables that meet either of the following criteria are generally not recoverable.

•

when there is a breach of financial covenants by the counterparty; or

•

information developed internally or obtained from external sources indicates that the debtor is unlikely to pay its creditors, including the Group, in full (without taking into account any collaterals held by the Group).

Irrespective of the above analysis, the Group considers that default has occurred when a financial asset is more than 90 days past due unless the Group has reasonable and supportable information to demonstrate that a more lagging default criterion is more appropriate.

(iii)

Credit-impaired financial assets

A financial asset is credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidence that a financial asset is credit-impaired includes observable data about the following events:

(a)

significant financial difficulty of the issuer or the borrower;

(b)

a breach of contract, such as a default or past due event;

(c)

the lender(s) of the borrower, for economic or contractual reasons relating to the borrower’s financial difficulty, having granted to the borrower a concession(s) that the lender(s) would not otherwise consider; or

(d)

it is becoming probable that the borrower will enter bankruptcy or other financial reorganization.

(iv)

Write-off policy

The Group writes off a financial asset when there is information indicating that the counterparty is in severe financial difficulty and there is no realistic prospect of recovery, e.g. when the counterparty has been placed under liquidation or has entered into bankruptcy proceedings, whichever occurs sooner. Financial assets written off may still be subject to enforcement activities under the Group’s recovery procedures, taking into account legal advice where appropriate. A write-off constitutes a derecognition event. Any subsequent recoveries are recognized in profit or loss.

(v)

Measurement and recognition of ECL

The measurement of ECL is a function of the probability of default, loss given default (i.e. the magnitude of the loss if there is a default) and the exposure at default. The assessment of the probability of default and loss given default is based on historical data and forward-looking information as described above. Estimation of ECL reflects an unbiased and probability-weighted amount that is determined with the respective risk of default occurring as the weights.

Generally, the ECL is the difference between all contractual cash flows that are due to the Group in accordance with the contract and the cash flows that the Group expects to receive, discounted at the effective interest rate determined at initial recognition.

Interest income is calculated based on the gross carrying amount of the financial asset unless the financial asset is credit-impaired, in which case interest income is calculated based on amortized cost of the financial asset.

The Group recognizes an impairment gain or loss in profit or loss for all financial instruments by adjusting their carrying amount.

Derecognition of financial assets

The Group derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset and an associated liability for amounts it may have to pay. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received.

On derecognition of a financial asset measured at amortized cost, the difference between the asset’s carrying amount and the sum of the consideration received and receivable is recognized in profit or loss.

Financial liabilities and equity

Classification as debt or equity

Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.

Equity instruments

An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Company are recognized at the proceeds received, net of direct issue costs.

Treasury shares

Our own equity instruments held by the Company or the Group (treasury shares) are recognized directly in equity at cost. No gain or loss is recognized in the profit or loss on the purchase, sale, issue or cancelation of the Company’s own equity instruments.

Financial liabilities

All financial liabilities are subsequently measured at amortized cost using the effective interest method or at FVTPL.

Financial liabilities at FVTPL

Financial liabilities are classified as at FVTPL when the financial liability is (i) contingent consideration of an acquirer in a business combination to which IFRS 3 Business Combinations applies, (ii) held for trading or (iii) it is designated as at FVTPL.

A financial liability is held for trading if:

•

it has been acquired principally for the purpose of repurchasing it in the near term; or

•

on initial recognition it is part of a portfolio of identified financial instruments that the Group manages together and has a recent actual pattern of short-term profit-taking; or

•

it is a derivative, except for a derivative that is a financial guarantee contract or a designated and effective hedging instrument.

A financial liability other than a financial liability held for trading or contingent consideration of an acquirer in a business combination may be designated as at FVTPL upon initial recognition if:

•

such designation eliminates or significantly reduces a measurement or recognition inconsistency that would otherwise arise; or

•

the financial liability forms part of a group of financial assets or financial liabilities or both, which is managed and its performance is evaluated on a fair value basis, in accordance with the Group’s documented risk management or investment strategy, and information about the grouping is provided internally on that basis; or

•

it forms part of a contract containing one or more embedded derivatives, and IFRS 9 permits the entire combined contract to be designated as at FVTPL.

For financial liabilities that are designated as at FVTPL, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognized in other comprehensive income, unless the recognition of the effects of changes in the liability’s credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss. For financial liabilities that contain embedded derivatives, such as convertible preferred shares, the changes in fair value of the embedded derivatives are excluded in determining the amount to be presented in other comprehensive income. The remaining amount of change in the fair value of liability is recognized in profit or loss. Changes in fair value attributable to a financial liability’s credit risk that are recognized in other comprehensive income are not subsequently reclassified to profit or loss; instead, they are transferred to accumulated losses upon derecognition of the financial liability.

Preferred shares

Preferred shares, which contain redemption features and other embedded derivatives, are designated as at financial liabilities at FVTPL.

Financial liabilities at amortized cost

Financial liabilities representing other payables and financial liabilities arising from unvested restricted shares are subsequently measured at amortized cost, using the effective interest method.

Derecognition of financial liabilities

The Group derecognizes financial liabilities when, and only when, the Group’s obligations are discharged, canceled or have expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss.

Derivative financial instruments

Derivatives are initially recognized at fair value at the date when derivative contracts are entered into and are subsequently remeasured to their fair value at the end of each reporting period. The resulting gain or loss is recognized in profit or loss.

Embedded derivatives

Derivatives embedded in non-derivative host contracts that are not financial assets within the scope of IFRS 9 are treated as separate derivatives when they meet the definition of a derivative, their risks and characteristics are not closely related to those of the host contracts and the host contracts are not measured at FVTPL.

Generally, multiple embedded derivatives in a single instrument that are separated from the host contracts are treated as a single compound embedded derivative unless those derivatives relate to different risk exposures and are readily separable and independent of each other.

Business Combination - Schedule of IFRS 2 Listing Expense (Detail) $ in Thousands	Mar. 29, 2023 USD ($) $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Shares	14,282
Fair Value	$ 39,800
Net liabilities of Maxpro	(5,724)
IFRS 2 Listing Expense	$ 45,524
Maxpro Public Stockholders [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Per Share Value \| $ / shares	$ 10.81
Shares	10,350
Fair Value	$ 111,884
Sponsor Parties [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Per Share Value \| $ / shares	$ 10.81
Shares	3,207
Fair Value	$ 34,668
Underwriter shares [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Per Share Value \| $ / shares	$ 10.81
Shares	26
Fair Value	$ 281
Maxpro Private Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Per Share Value \| $ / shares	$ 0.12
Shares	619
Fair Value	$ 74
Maxpro Public Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Per Share Value \| $ / shares	$ 0.12
Shares	10,350
Fair Value	$ 1,242
Redemptions of Maxpro class A common stock [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Per Share Value \| $ / shares	$ 10.55
Redemptions of stock	(10,270)
Fair Value	$ (108,349)

Restricted Net Assets	12 Months Ended
Restricted Net Assets	Dec. 31, 2023
Restricted Assets [Abstract]
Restricted Net Assets	34. RESTRICTED NET ASSETS The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its subsidiaries. The Company’s PRC subsidiaries are subject to relevant PRC statutory laws and regulations which permit payments of dividends only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with IFRSs differ from those reflected in the statutory financial statements of the Company’s PRC subsidiaries. Foreign exchange and other regulations in the PRC further restrict the Company’s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances. As of December 31, 2022 and 2023, amounts restricted are the paid-in capital of the Company’s PRC subsidiaries, which amounted to $52,298 and $35,000, respectively.

Schedule I - Additional Information (Detail)	12 Months Ended
Schedule I - Additional Information (Detail)	Dec. 31, 2023
Disclosure of Additional Information Explanatory [Line Items]
Minimum percentage requirement	25.00%

Plant and Equipment - Additional Information (Detail)	12 Months Ended
Plant and Equipment - Additional Information (Detail)	Dec. 31, 2023
Bottom of Range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	3 years
Top of Range [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives	5 years

Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about intangible assets [abstract]

Summary of Intangible Assets


	Patent rights (available for use)			Patent rights (not yet available for use)			Total
	(note i)			(note ii)
COST
As of January 1, 2021	$	375		$	11,000		$	11,375
Addition		—			7,500			7,500
As of December 31, 2021, 2022 and 2023		375			18,500			18,875
AMORTIZATION AND IMPAIRMENT
As of January 1, 2021		(57	)		(1,000	)		(1,057	)
Charge for the year		(20	)		—			(20	)
Impairment loss recognized		—			(3,000	)		(3,000	)
As of December 31, 2021		(77	)		(4,000	)		(4,077	)
Charge for the year		(20	)		—			(20	)
As of December 31, 2022		(97	)		(4,000	)		(4,097	)
Charge for the year		(21	)		—			(21	)
As of December 31, 2023		(118	)		(4,000	)		(4,118	)
CARRYING VALUES
As of December 31, 2021	$	298		$	14,500		$	14,798
As of December 31, 2022	$	278		$	14,500		$	14,778
As of December 31, 2023	$	257		$	14,500		$	14,757

Notes:

(i)

The patent rights grant the Group the right to use certain scientific data for research and manufacture of pipelines, namely APL-501, APL-502 and APL-509.

(ii)

Other Income (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of Detailed Information about Other Income [Line Items]

Summary of Information about Other Income


	Years Ended December 31,
	2021		2022		2023
Interest income	$	467	$	431	$	753
Government grants (note i)		587		1,016		464
Total	$	1,054	$	1,447	$	1,217

Right-of-Use Assets (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of quantitative information about right-of-use assets [abstract]

Summary of Quantitative Information about Right-of-Use Assets


				Plant and
	Offices			equipment			Total
COST
As of January 1, 2022	$	2,367		$	62		$	2,429
Additions		538			10			548
Derecognized upon end of lease term		(40	)		(13	)		(53	)
As of December 31, 2022		2,865			59			2,924
Additions		—			12			12
Derecognized upon end of lease term		(291	)		(46	)		(337	)
As of December 31, 2023		2,574			25			2,599
ACCUMULATED DEPRECIATION
As of January 1, 2022		(1,349	)		(44	)		(1,393	)
Provided for the year		(579	)		(14	)		(593	)
Derecognized upon end of lease term		40			13			53
As of December 31, 2022		(1,888	)		(45	)		(1,933	)
Provided for the year		(568	)		(19	)		(587	)
Derecognized upon end of lease term and foreign exchange effect		296			50			346
As of December 31, 2023		(2,160	)		(14	)		(2,174	)
CARRYING VALUES
As of December 31, 2022	$	977		$	14		$	991
As of December 31, 2023	$	414		$	11		$	425

Summary of Right-of-Use-Assets Depreciated Over Lease Term

The right-of-use assets are depreciated over the lease terms using straight-line method.


	Years ended December 31,
	2021		2022		2023
Expense relating to short-term leases	$	56	$	96	$	122
Total cash outflow for leases	$	667	$	782	$	566

Intangible Assets

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about intangible assets [abstract]

Intangible Assets

17.

INTANGIBLE ASSETS


	Patent rights (available for use)			Patent rights (not yet available for use)			Total
	(note i)			(note ii)
COST
As of January 1, 2021	$	375		$	11,000		$	11,375
Addition		—			7,500			7,500
As of December 31, 2021, 2022 and 2023		375			18,500			18,875
AMORTIZATION AND IMPAIRMENT
As of January 1, 2021		(57	)		(1,000	)		(1,057	)
Charge for the year		(20	)		—			(20	)
Impairment loss recognized		—			(3,000	)		(3,000	)
As of December 31, 2021		(77	)		(4,000	)		(4,077	)
Charge for the year		(20	)		—			(20	)
As of December 31, 2022		(97	)		(4,000	)		(4,097	)
Charge for the year		(21	)		—			(21	)
As of December 31, 2023		(118	)		(4,000	)		(4,118	)
CARRYING VALUES
As of December 31, 2021	$	298		$	14,500		$	14,798
As of December 31, 2022	$	278		$	14,500		$	14,778
As of December 31, 2023	$	257		$	14,500		$	14,757

Notes:

(i)

The patent rights grant the Group the right to use certain scientific data for research and manufacture of pipelines, namely APL-501, APL-502 and APL-509.

(ii)

The patent rights (available for use) have finite lives and are amortized on a straight-line basis. The useful lives of patent rights ranged between 10 to 18 years for the years ended December 31, 2021, 2022 and 2023. The useful lives of patent rights were determined by the management of the Group taking into account the period over which the patent rights are expected to be available for use by the Group and the stability of the industry.

Financial Instruments - Summary of Internal Credit Risk Grading Assessment Comprises (Detail) - Financial Assets at Amortized Cost [Member]	12 Months Ended
	Dec. 31, 2023
Low Risk [Member]
Disclosure of internal credit grades [line items]
Description	The counterparty has a low risk of default and does not have any past-due amounts
Financial assets at amortized cost	12-month ECL
Watch List [Member]
Disclosure of internal credit grades [line items]
Description	Debtor frequently repays after due dates but settles the amounts in full
Financial assets at amortized cost	12-month ECL
Doubtful [Member]
Disclosure of internal credit grades [line items]
Description	There have been significant increases in credit risk since initial recognition through information developed internally or external resources
Financial assets at amortized cost	Lifetime ECL- not credit-impaired
Loss [Member]
Disclosure of internal credit grades [line items]
Description	There is evidence indicating the asset is credit-impaired
Financial assets at amortized cost	Lifetime ECL- credit-impaired
Write-off [Member]
Disclosure of internal credit grades [line items]
Description	There is evidence indicating that the debtor is in severe financial difficulty and the Group has no realistic prospect of recovery
Financial assets at amortized cost	Amount is written off

Income Tax Expenses - Summary of Income Tax Expense Income Reconciled to Loss Before Taxation as Per Consolidated Statements (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Reconciliation of accounting profit multiplied by applicable tax rates [abstract]
Loss before taxation	$ (172,591)	$ (240,810)	$ (94,796)
Tax at the US federal tax rate of 21%	(36,244)	(50,570)	(19,907)
Tax effect of expenses not deductible for tax purpose	568	45,739	20,419
Tax effect of income not taxable for tax purpose	0	(257)	(309)
Tax effect of additional qualified expenses deductible for tax purpose (note)	(741)	(1,517)	(0)
Tax effect of R&D Credits	(2,311)	0	0
Tax effect of tax losses not recognized	10,277	7,027	360
Tax effect of foreign tax differential rates	(28,461)	(421)	(562)
Income tax expense	$ 10	$ 1	$ 1

Related Party Disclosures (Tables)

12 Months Ended

Dec. 31, 2023

Summary of Transactions with Related Party

(i)

Compensation of key management personnel

The remuneration of directors of the Company and other members of key management were as follows:


	For the year ended December 31,
	2021		2022		2023
Short term benefits	$	2,214	$	2,473	$	4,112
Retirement benefit scheme contributions		12		12		21
Share-based payment		6,131		1,820		9,419
	$	8,357	$	4,305	$	13,552

General Information

12 Months Ended

Dec. 31, 2023

General Information [Abstract]

General Information

GENERAL INFORMATION

Apollomics Inc. (“Apollomics” or the “Company”) is a clinical-stage biotechnology company focused on discovering and developing oncology therapies to address unmet medical needs. Since the Company’s founding in 2015, the Company has built a pipeline of nine drug candidates across 11 programs that focus on oncology, of which six drug candidates are in the clinical stage.

The Company was originally formed as CB Therapeutics Inc. as a result of a spin-off of Crown Bioscience International, which was completed on December 31, 2015. Prior to December 2015, Crown Bioscience International, through its subsidiaries, was the owner of certain patent rights relating to certain of these drug candidates. In order to focus on its core business, namely providing preclinical contract research organization services, and allow the drug discovery and development related business to be operated and financed separately, Crown Bioscience International spun off its Taiwan subsidiary, Crown Bioscience (Taiwan), and contributed it to the Company. As a result, we became the owner of these patent rights.

In addition to its U.S. headquarters, the Company also has locations in Australia (Apollomics (Australia) Pty Ltd, formed in November 2016), Hong Kong (Apollomics (Hong Kong) Limited, formed in June 2019) and China (Zhejiang Crownmab Biotech Co. Ltd. and Zhejiang Crown Bochuang Biopharma Co. Ltd., formed in May 2018 and May 2020, respectively). The Company’s headquarters and global drug development team is based in the United States (San Francisco Bay area), while its discovery and China drug development team is based in China (Hangzhou and Shanghai). The Company operates in both the United States and China, with its headquarters and its global drug development team in the San Francisco Bay Area and its discovery and China drug development team in Hangzhou and Shanghai, China.

On March 29, 2023 ( “Closing Date”), Apollomics consummated a business combination (the “Business Combination”) with Maxpro Capital Acquisition Corp. (“Maxpro”), a Delaware corporation and special purpose acquisition company, pursuant to the initial business combination agreement dated September 14, 2022 and subsequent amendment to the business combination agreement dated February 9, 2023 (the “Business Combination Agreement” or “BCA”). In connection with the closing of the Business Combination, Apollomics became a publicly traded company on the Nasdaq Capital Market (“Nasdaq”). The Company’s Class A Ordinary Shares and warrants are listed on Nasdaq under the trading symbols “APLM” and “APLMW,” respectively. Trading on the Nasdaq commenced on March 30, 2023.

The consolidated financial statements are presented in U.S. dollars (“$”). The Company's subsidiaries included in the consolidated financial statements are listed below (the Company and its subsidiaries are collectively referred to herein as the “Group”). These consolidated financial statements have been prepared based on the accounting policies which conform with International Financial Reporting Standards (“IFRSs”) as issued by the International Accounting Standards Board (“IASB”) and have been prepared under the assumption the Company operates on a going concern basis.


Name of subsidiaries	Place of incorporation or establishment/operation and date of incorporation/establishment	Principal activities
Apollomics, Inc.	California, United States January 14, 2016	Research and development of drugs
Apollomics (Australia) Pty. Ltd.	Melbourne, Australia November 4, 2016	Research and development of drugs
Apollomics (Hong Kong) Limited	Hong Kong, China June 24,2019	Investment holding
Zhejiang Crownmab Biotech Co., Ltd.	Hangzhou, China May 29, 2018	Investment holding and research and development of drugs
Zhejiang Crown Bochuang Biopharma Co., Ltd.	Hangzhou, China May 29, 2020	Research and development of drugs
Project Max SPAC Merger Sub, Inc.	Delaware, United States August 19, 2022	Investment holding

Retirement Benefits Plan - Additional information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee benefits [Abstract]
Total cost charged to profit or loss	$ 499	$ 662	$ 749

Time Deposits with Original Maturity Over Three Months/Cash and Cash Equivalents - Additional Information (Detail)	Dec. 31, 2023	Dec. 31, 2022
Bottom of Range [Member]
Disclosure Of Time Deposits With Banks [Line Items]
Time deposits, interest rate	0.01%	0.01%
Top of Range [Member]
Disclosure Of Time Deposits With Banks [Line Items]
Time deposits, interest rate	3.05%	0.05%
Fixed Interest Rate [Member]
Disclosure Of Time Deposits With Banks [Line Items]
Time deposits, interest rate	3.70%

General Information (Tables)

12 Months Ended

Dec. 31, 2023

General Information [Abstract]

Summary of Information about Consolidated Financial Statements and Company Principal Subsidiaries


Name of subsidiaries	Place of incorporation or establishment/operation and date of incorporation/establishment	Principal activities
Apollomics, Inc.	California, United States January 14, 2016	Research and development of drugs
Apollomics (Australia) Pty. Ltd.	Melbourne, Australia November 4, 2016	Research and development of drugs
Apollomics (Hong Kong) Limited	Hong Kong, China June 24,2019	Investment holding
Zhejiang Crownmab Biotech Co., Ltd.	Hangzhou, China May 29, 2018	Investment holding and research and development of drugs
Zhejiang Crown Bochuang Biopharma Co., Ltd.	Hangzhou, China May 29, 2020	Research and development of drugs
Project Max SPAC Merger Sub, Inc.	Delaware, United States August 19, 2022	Investment holding

Finance Costs - Summary of Information about Finance Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Finance Cost [Abstract]
Interest expenses on lease liabilities	$ 150	$ 93	$ 83

Share-Based Payment Transaction - Summary of Share-Based Payment Transactions (Detail) - Two Thousand and Sixteen Plan [Member]	12 Months Ended
	Dec. 31, 2023 yr $ / shares	Dec. 31, 2022 yr $ / shares	Dec. 31, 2021 yr $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of share options granted		$ 0.31
Exercise price as converted		$ 4.32
Expected volatility (note)	72.50%
Expected life \| yr	6.25	6.078	6.078
Risk-free rate	3.67%
Expected dividend yield	0.00%	0.00%	0.00%
Bottom of Range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date option fair value per share	$ 0.01	$ 0.0933	$ 0.143
Exercise price of share options granted	0.07		0.26
Grant date option fair value per share as converted	0.14	$ 1.302	1.995
Exercise price as converted	0.94		$ 3.63
Expected volatility (note)		75.00%	75.00%
Risk-free rate		1.35%	0.51%
Top of Range [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Grant date option fair value per share	0.511	$ 0.1517	$ 0.1544
Exercise price of share options granted	0.72		0.31
Grant date option fair value per share as converted	7.127	$ 2.116	2.154
Exercise price as converted	$ 10.01		$ 4.32
Expected volatility (note)		77.50%	80.00%
Risk-free rate		3.98%	1.09%

Financial Liabilities Arising from Unvested Restricted Shares (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of financial liabilities [abstract]

Summary of Financial Liabilities Arising From Unvested Restricted Shares


	As of December 31,
	2022		2023
Payables in respect of unvested restricted shares attributable to:
Dr. Yu (the chief executive of the Company)	$	68	$	—

Other Income - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2023 AUD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 AUD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Australia [Member]
Disclosure of Detailed Information about Other Income [Line Items]
Income from government grants related to research and development activity	$ 635	$ 408,000	$ 1,353	$ 908,000	$ 0

Deposits, Prepayments and Deferred Expenses (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of Deposits Prepayments and Deferred Expenses [Abstract]

Disclosure of Detailed Information about Deposits Prepayments and Deferred Expenses Explanatory


	As of December 31,
	2022		2023
Other prepayments	$	624	$	1,073
Prepaid taxes	—			312
Value-Added Tax recoverable		547		466
Deposits		5		7
Payment in advance to suppliers	—			250
	$	1,176	$	2,108

Share-Based Payment Transactions - Summary of Company's Share Options (Detail) $ in Thousands		12 Months Ended
	Mar. 29, 2023 USD ($)	Dec. 31, 2023 shares $ / shares	Dec. 31, 2022 shares $ / shares	Dec. 31, 2021 shares $ / shares
Disclosure Of Movement In The Share Options [Line Items]
Number of Options, Granted \| $	14,282
Two Thousand and Sixteen Plan [Member]
Disclosure Of Movement In The Share Options [Line Items]
Number of Options, Beginning		135,979,705	155,059,183	151,133,235
Number of Options, Granted			11,500,000	39,715,000
Number of Options,Exercised			(8,552,187)	(6,511,135)
Number of Options, Forfeited			(22,027,291)	(29,277,917)
Number of Options, Ending			135,979,705	155,059,183
Number of Option, Excercisable			67,667,737	78,269,054
Weighted average exercise price, Beginning \| $ / shares		$ 0.217	$ 0.203	$ 0.169
Weighted average exercise price, Granted \| $ / shares			0.31	0.279
Weighted average exercise price, Exercised \| $ / shares			0.046	0.022
Weighted average exercise price, Forfeited \| $ / shares			0.232	0.169
Weighted average exercise price, Ending \| $ / shares			$ 0.217	$ 0.203
Exchange Ratio of 0.071679 [Member]
Disclosure Of Movement In The Share Options [Line Items]
Number of Options, Beginning		9,746,889	11,114,486	10,833,079
Number of Options, Granted		3,048,310	824,309	2,846,731
Number of Options,Exercised		62,443	613,012	466,712
Number of Options, Forfeited		808,341	1,578,894	2,098,612
Number of Options, Ending		11,924,415	9,746,889	11,114,486
Number of Option, Excercisable		7,859,478	4,850,356	5,610,248
Weighted average exercise price, Beginning \| $ / shares		$ 3.027	$ 2.832	$ 2.358
Weighted average exercise price, Granted \| $ / shares		9.927	4.325	3.892
Weighted average exercise price, Exercised \| $ / shares		1.397	0.642	0.307
Weighted average exercise price, Forfeited \| $ / shares		0.57	3.237	2.238
Weighted average exercise price, Ending \| $ / shares		$ 4.615	$ 3.027	$ 2.832

Business Combination

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about business combination [abstract]

Business Combination

BUSINESS COMBINATION

As previously outlined in Note 1 – General Information, the Company underwent a Business Combination with Maxpro on March 29, 2023. The Business Combination was effected through the issuance of shares of Apollomics to Maxpro stockholders.

Upon the closing of the Business Combination, the following occurred:

Each Apollomics ordinary share assumed outstanding immediately prior to the closing of the Business Combination, which totaled 401,804,327 shares (other than the exercise of stock option), was exchanged for the right to receive 0.071679 shares of post-closing Apollomics Ordinary Shares (the “Exchange Ratio”). The resulting issuance totaled 28,800,926 shares of Apollomics Class B Ordinary Shares. No Class B Ordinary Share is transferable, except to certain permitted transferees, until the earlier of (i) six (6) months after the Closing Date, which is September 29, 2023, or (ii) in the event that a definitive agreement that contemplates a change of control of is entered into, immediately prior to the consummation of such Change of Control (the “Class B Lock-Up Period”), subject to the conditions set forth in the memorandum and articles of association (“MAA”). Class B Ordinary Shares will be automatically converted into Class A Ordinary Shares on a one-to-one basis upon the end of the Class B Lock-Up Period, provided that the Board may approve such conversion prior to the end of the Class B Lock-Up Period.

In connection with the Business Combination, Apollomics entered into the PIPE Financing with certain accredited investors for an aggregate of 230,000 Class B Ordinary Shares at a price of $10.00 per share, 2,135,000 Series A Preferred Shares at a price of $10.00 per share and 57,500 Penny Warrants to purchase Class A Ordinary shares, for a total of $23.7 million.

Each share of Maxpro Class A Common Stock (consisting of non-redeemable Common Stock and redeemable Common Stock that was not redeemed at closing) assumed outstanding immediately prior to the closing of the Business Combination was exchanged for, on a one-for-one basis, shares of Apollomics Class A Ordinary Shares.

Each share of Maxpro Class B Common Stock (consisting of non-redeemable Common Stock) assumed outstanding immediately prior to the closing of the Business Combination was exchanged for, on a one-for-one basis, shares of Apollomics Class A Ordinary Shares.

In connection with the Business Combination, Maxpro’s stockholders redeemed 10,270,060 out of the 10,350,000 public shares available, representing 99.2% of Maxpro’s public float, which resulted in Apollomics receiving nominal cash in connection with the Business Combination other than through the PIPE Financing. At closing of the Business Combination, 10,350,000 Maxpro public warrants and 464,150 Maxpro private warrants outstanding were assumed by Apollomics and recorded as a warrant liability on the Company’s consolidated statement of financial position. The warrant liability will be remeasured each reporting period until the earlier of the warrant expiration date or the warrant

exercise date. The Private Warrants or Extension Warrants (including the Class A Ordinary Shares issuable upon exercise of any of such warrants) can not be transferred, assigned or sold until September 29, 2023, the date that is six months after the Closing Date, pursuant to the Lock-Up Agreement effective at the Closing Date.

Maxpro had a promissory note payable to the Maxpro Sponsor with a principal balance of $1.5 million immediately prior to the closing of the Business Combination. The unpaid principal amount was converted into 155,250 shares of Apollomics Class A Ordinary Shares and 155,250 private warrants upon the closing of the Business Combination. The warrants were recorded as a warrant liability on the Company's consolidated statement of financial position. The warrant liability will be remeasured each reporting period until the earlier of the warrant expiration date or the warrant exercise date.

Each Maxpro warrant issued and outstanding immediately prior to the closing of the Business Combination was assumed by Apollomics and became exercisable, on a one-for-one basis, for Apollomics Class A Ordinary Shares.

Prior to the closing of the Business Combination, one Apollomics stock option holder elected to exercise all of such holder’s options, resulting in the issuance of 435,833 shares of Apollomics Class A Common Stock, which upon the closing of the Business Combination, were canceled and exchanged for the right to receive .071679 shares of Apollomics Class A Ordinary Shares per share of Apollomics Class A Common Stock, which resulted in the issuance of 31,240 shares of Apollomics Class A Ordinary Shares. In addition, each outstanding option to purchase a Pre-Closing Apollomics Ordinary Share, whether vested or unvested, immediately prior to the Merger, was also adjusted such that each option (i) has the right to acquire a number of Apollomics Class B Shares equal to (as rounded down to the nearest whole number) the product of (A) the number of Pre-Closing Apollomics Ordinary Shares which the option had the right to acquire immediately prior to the Share Split, multiplied by (B) the Exchange Ratio; and (ii) have an exercise price equal to (as rounded up to the nearest whole cent) the quotient of (A) the exercise price of the option immediately prior to the Share Split, divided by (B) the Exchange Ratio.

The net proceeds from the PIPE Financing and Business Combination, totaled $20.2 million.

The following table presents the total Apollomics common stock outstanding immediately after the closing of the Business Combination:


	Number of Shares
Exchange of Maxpro Class A common stock for post-closing Apollomics Class A Ordinary Shares		490,025
Exchange of Maxpro Class B common stock for post-closing Apollomics Class A Ordinary Shares		2,587,500
Exchange of Maxpro Class A common stock subject to possible redemption that was not redeemed for post-closing Apollomics Class A Ordinary Shares		79,940
Issuance of post-closing Apollomics Class A Ordinary Shares to Maxpro Sponsor in connection with conversion of a convertible promissory note		155,250
Subtotal - Business Combination, net of redemptions		3,312,715
Issuance of post-closing Apollomics Class B ordinary shares to PIPE Investors		230,000
Conversion of pre-closing Apollomics convertible preferred shares (converted into pre-closing Apollomics ordinary shares prior to the Business Combination) into Post-Closing Apollomics Ordinary Shares		54,420,956
Issuance of Post-Closing Apollomics Ordinary Shares in connection with the Business Combination due to exercise of pre-closing Apollomics stock options prior to the Business Combination		31,240
Total - Post-Closing Apollomics Ordinary Shares outstanding as a result of Business Combination, PIPE Financing, conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares, and issuance of shares upon Closing due to pre-Closing exercise of stock options (note i)		57,994,911

Note i: In addition to the 57,994,911 shares specified above, the following shares were included in the total 89,495,790 Post- Closing Apollomics Ordinary Shares outstanding as of December 31, 2023 on the consolidated statement of changes in stockholders' deficit: 1) 28,800,926 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the exchange of all Pre-Closing Apollomics Ordinary Shares outstanding as of December 31, 2022 at the Exchange Ratio 2) 2,668,750 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the conversion of Post-Closing Apollomics Series A Preferred Shares into Post-Closing Apollomics Class A Ordinary Shares in May 2023 at a conversion ratio of 1 to 1.25 3) 16,202 Post-Closing Apollomics Ordinary Shares were outstanding as a result of the exercise of stock options in April 2023, and 15,000 Ordinary Shares as a result of the exercise of stock options in November 2023.

As Maxpro did not meet the definition of a business in accordance with IFRS 3 (“Business Combinations”), the transaction was accounted for within the scope of IFRS 2 (“Share-based Payment”) as a share-based payment transaction in exchange for a public listing service. As such, the fair value of Apollomics shares transferred to Maxpro stockholders in excess of the net identifiable assets of Maxpro represents compensation for the service of a stock exchange listing for its shares and is accounted for as an expense in post-closing Apollomics at the consummation of the Business Combination. The net identifiable assets of Maxpro were stated at

historical cost, with no goodwill or other intangible assets recorded. Apollomics was deemed to be both the legal and accounting acquirer given that subsequent to the Business Combination:

Apollomics' shareholders have a majority of the voting power of post-closing Apollomics;

Apollomics’ operations comprise all of the ongoing operations of post-closing Apollomics;

Apollomics controls a majority of the governing body of post-closing Apollomics;

Apollomics’ senior management comprise all of the senior management of post-closing Apollomics.

Under IFRS 2, Apollomics recorded a one-time share-based expense of $45.5 million at the closing of the Business Combination that was calculated based on the excess of the fair value of Apollomics over the fair value of the identifiable net assets of Maxpro that were acquired. The amount of Maxpro’s identifiable net assets acquired at Closing were as follows:


Cash and cash equivalents	$	954
Notes payable – sponsor		(1,999	)
Accrued liabilities		(1,056	)
Deferred underwriting compensation		(3,623	)
Total Maxpro identifiable net liabilities at fair value	$	(5,724	)

The net assets of Maxpro are stated at fair value with no goodwill or other intangible assets recorded. The IFRS 2 listing expense was calculated as follows:


	Per Share Value (at March 29, 2023)		Shares (in thousands)			Fair Value (in thousands)
Maxpro public stockholders	$	10.81		10,350		$	111,884
Sponsor parties		10.81		3,207			34,668
Underwriter shares		10.81		26			281
Maxpro private warrants		0.12		619			74
Maxpro public warrants		0.12		10,350			1,242
Redemptions of Maxpro class A common stock		10.55		(10,270	)		(108,349	)
				14,282			39,800
Net liabilities of Maxpro							(5,724	)
IFRS 2 Listing Expense						$	45,524

The prior year’s shares and per share numbers have been retrospectively adjusted for the Exchange Ratio of 0.071679.

Related Party Disclosures - Summary of Compensation of Key Management Personnel (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Compensation of Key Management Personnel [Line Items]
Short term benefits	$ 4,112	$ 2,473	$ 2,214
Retirement benefit scheme contributions	21	12	12
Share-based payment	9,419	1,820	6,131
Total key management personnel compensation	$ 13,552	$ 4,305	$ 8,357

Capital Risk Management

12 Months Ended

Dec. 31, 2023

Capital Risk Management [Abstract]

Capital Risk Management

28.

CAPITAL RISK MANAGEMENT

The Group manages its capital to ensure the Group will be able to continue as a going concern while maximizing the return to stakeholders through the optimization of the debt and equity balance. The Group’s overall strategy remains unchanged throughout the years ended December 31, 2021, 2022 and 2023.

The capital structure of the Group consists of net debt, which includes lease liabilities and Preferred Shares as disclosed in Notes 23 and 24, respectively, net of cash and cash equivalents, and equity attributable to owners of the Company, comprising issued share capital, share premium, accumulated losses and various reserves.

We regularly review the capital structure from time to time. As part of this review, we consider the cost of capital and the risks associated with each class of capital. We may balance our overall capital structure through the payment of dividends, new share issues as well as raising new debt or redemption of existing debts.

Convertible Preferred Shares

12 Months Ended

Dec. 31, 2023

Convertible Preferred Shares [Abstract]

Convertible Preferred Shares

25.

CONVERTIBLE PREFERRED SHARES

The Company entered into preferred share subscription agreements with several independent investors and the details of issued preferred shares (the “Preferred Shares”) are set out as follows:


	Date of issue	Total number of Preferred Shares issue		Subscription price per share		Subscription price total
	July 26, 2016 to
Series A1 Preferred Shares	July 28, 2016		88,038,389	$	0.04543	$	4,000
	January 31, 2019		44,019,194		0.04543		2,000
			132,057,583				6,000
Series A2 Preferred Shares	July 21, 2017 to
	July 25, 2017		73,371,157		0.05111		3,750
	September 19, 2018 to
Series B Preferred Shares	December 27, 2018		260,709,579		0.3329		86,800
	January 8, 2019 to
	March 25, 2019		36,643,370		0.3329		12,200
			297,352,949				99,000
	September 10, 2020 to
Series C Preferred Shares	September 30, 2020		141,692,465		0.4845		68,650
	October 5, 2020 to
	November 5, 2020		114,757,479		0.4845		55,600
			256,449,944				124,250

The exchange ratio has been applied to these preferred shares to give effect to the Business Combination of March 29, 2023 and these would have been as follows:


	Date of issue	Total number of Preferred Shares issue		Subscription price per share		Subscription price total
	July 26, 2016 to
Series A1 Preferred Shares	July 28, 2016		6,310,503	$	0.6338	$	4,000
	January 31, 2019		3,155,252		0.6338		2,000
			9,465,755				6,000
Series A2 Preferred Shares	July 21, 2017 to
	July 25, 2017		5,259,170		0.7130		3,750

	September 19, 2018 to
Series B Preferred Shares	December 27, 2018		18,687,400		4.6443		86,800
	January 8, 2019 to
	March 25, 2019		2,626,559		4.6443		12,200
			21,313,959				99,000

	September 10, 2020 to
Series C Preferred Shares	September 30, 2020		10,156,372		6.7593		68,650
	October 5, 2020 to
	November 5, 2020		8,225,701		6.7593		55,600
			18,382,073				124,250

The key terms of the Preferred Shares are as follows:

(a)

Dividends rights

The Company cannot declare, pay or set aside any dividends on ordinary shares in any year unless the Preferred Shares holders shall first receive, or simultaneously receive, such dividends. Should any dividends be declared as determined by the Company, the Company will declare dividends at a rate of 8% per annum of the original issue price of Series A1 Preferred Shares, Series A2 Preferred Shares, Series B Preferred Shares and Series C Preferred Shares on each Series A1 Preferred Share, Series A2 Preferred Share, Series B Preferred Share and Series C Preferred Share, respectively.

Payments of any dividends to the holders of the Preferred Shares shall be on a pro rata, pari passu basis in proportion to the dividend rates for each series of the Preferred Shares. Such dividends shall be non-cumulative. After payment of such dividends, any additional dividends shall be distributed among the holders of the Preferred Shares and ordinary shares pro rata based on the number of ordinary shares or as-if converted basis then held by each holder.

No dividends have been declared by the Company up to the date of this report.

(b)

Conversion feature

Each holder of the Preferred Shares shall have the rights to convert the Preferred Shares into ordinary shares at any time after the issuance date into such number of fully paid and non-assessable ordinary shares as determined by dividing the relevant issue price by the then-effective conversion price. The “Conversion Price” shall initially be the Preferred Shares issue price, resulting in an initial conversion ratio of 1:1, and shall be subject to adjustment and readjustment (including but not limited to share splits and subdivision, additional ordinary shares issued and adjustment upon issuance of any other Preferred Shares for less than the Conversion Price). As of December 31, 2022 and March 29, 2023, the applicable conversion ratio was 1:1.

All outstanding Preferred Shares shall automatically be converted upon listing, at the applicable conversion ratio in effect at the time of conversion, without the payment of any additional consideration, into fully-paid and non-assessable ordinary shares upon the earlier of (i) the closing of a qualified initial public offering (“QIPO”), or (ii) the date specified by vote or written consent of the holders of at least a majority of the then outstanding Preferred Shares, voting together as a single class, at the Conversion Price in effect at such time.

QIPO means the closing of a firm commitment underwritten registered public offering by the Company of its ordinary shares on a nationally recognized securities exchange in the US, Hong Kong or the PRC or any other jurisdiction approved by the board of directors of the Company, that reflects a pre-offering valuation of the Company which is not less than a value as stated in the convertible Preferred Share subscription agreements.

(c)

Redemption feature

Series A Preferred Shares

Neither the holders of Series A Preferred Shares nor the Company shall have the unilateral right to call or redeem or cause to have called or redeemed any of the outstanding Series A Preferred Shares.

Series B Preferred Shares and Series C Preferred Shares

Upon the written request of any holders of Series B Preferred Shares and Series C Preferred Shares, the Company shall redeem the outstanding Series B Preferred Shares and Series C Preferred Shares (collectively as the “Redeeming Preferred Shares”) of such holder(s) of Series B Preferred Shares and Series C Preferred Shares (collectively as the “Redeeming Preferred Shareholders”), respectively, if the Company has not completed a QIPO by December 31, 2021 and such redemption has to be completed within eighteen (18) months after redemption notice is served. In August, September and December 2022, the Company received written requests from certain convertible preferred shareholders to redeem the preferred shares held by them in accordance with the contractual redemption terms.

The redemption feature shall be automatically terminated upon the submission of application of QIPO (“Listing Application”) and will be automatically restored to the fullest effect immediately upon (i) the Company withdrawing its Listing Application, or (ii) the Listing Application failing to consummate within 18 months from closing date of Series C Preferred Shares (i.e. May 2022). As at 31 December 2022, the redemption feature was fully restored.

The redemption price shall be paid by the Company to each of the Redeeming Preferred Shareholders in an amount equal to the higher of the following:

(i)

the sum of (a) 100% of the original issue price of the Redeeming Preferred Shares; (b) annual interest calculated at a simple interest of 12% per annum on the original issue price of the Redeeming Preferred Shares for the period of time from the date on which the Redeeming Preferred Shares are first issued by the Company until the date of full payment of the redemption price for the Redeeming Preferred Shares; and (c) all accrued or declared but unpaid dividends on the Redeeming Preferred Shares as calculated on day of receipt by the Company of the redemption notice given by the Redeeming Preferred Shareholders; and

(ii)

a fraction, the numerator of which is the latest amount of the audited net assets of the Company prior to the day of full payment of redemption price, and the denominator of which is the total number of ordinary shares of the Company (on an as converted and fully diluted basis) on the day of receipt by the Company of the redemption notice given by the Redeeming Preferred Shareholders.

As at December 31, 2022, the Group classified the Preferred Shares as non-current liabilities on the basis that the Group has the unconditional right to defer settlement for at least twelve months from the reporting date. With the completion of De-SPAC, all the Series A, B, C Preferred Shares had been converted into ordinary shares of the Company on March 29, 2023, those previously received redemption notices were not valid anymore. On March 29, 2023, all the preferred shares were converted into common shares, and therefore as of December 31, 2023, there are no longer any Preferred Shares.

(d)

Liquidation preferences

Series A Preferred Shares

If there are any assets or funds remaining after the aggregate Series B Preference Amount (as defined below under “Series B Preferred Shares”) and Series C Preference Amount (as defined below under “Series C Preferred Shares”) have been distributed or paid in full to the holders of Series B Preferred Shares and Series C Preferred Shares, the holders of the Series A Preferred Shares shall receive 100% of the Series A Preferred Shares original issue price plus all accrued or declared but unpaid dividends. If upon the occurrence of a Liquidation Event, there is insufficient fund to pay the aforesaid amount to the holders of the Series A Preferred Shares, then the entire assets and funds of the Company legally available for distribution to all members of the Company shall be distributed ratably among the holders of Series A Preferred Shares, on a pari passu basis with each other, in proportion to the aggregate amount to be paid to each such Series A Preferred Shares holder is otherwise entitled to receive.

Series B Preferred Shares

If there are any assets or funds remaining after the aggregate Series C Preference Amount has been distributed or paid in full to the holders of Series C Preferred Shares, the Series B Preferred Shares holders shall be paid out of the remaining legally available funds for distribution and in preference to any distribution of any of the assets or funds of the Company to the holders of the Series A Preferred Shares and the holders of ordinary shares an amount equal to 100% of the Series B Preferred Shares original issue price

plus a simple interest at the rate of 12% per annum plus all accrued or declared but unpaid dividends (the “Series B Preference Amount”). If upon the occurrence of a Liquidation Event, there is insufficient fund to pay the Series B Preference Amount, then the entire assets and funds of the Company legally available for distribution to all members of the Company shall be distributed ratably among the holders of the Series B Preferred Shares, on a pari passu basis with each other, in proportion to the aggregate Series B Preference Amount to be paid to each such Series B Preferred Shares holder is otherwise entitled to receive.

Series C Preferred Shares

In the event of a Liquidation Event of the Company, the holders of Series C Preferred Shares shall be entitled to receive, pari passu with each other, in preference and prior to any distribution of any of the assets of the Company to the holders of ordinary shares or members of any other class or series of shares by reason of their status as such holder or member, an amount equal to 100% of the Series C Preferred Shares original issue price plus a simple interest at the rate of 12% per annum plus all accrued or declared but unpaid dividends (the “Series C Preference Amount”). If upon the occurrence of a Liquidation Event, the assets and funds thus distributed among the holders of the Series C Preferred Shares shall be insufficient to permit the payment of the aggregate Series C Preference Amount, then the entire assets and funds of the Company legally available for distribution to all holders of Series C Preferred Shares shall be distributed ratably among the holders of the Series C Preferred Shares, pari passu with each other, in proportion to the aggregate Series C Preference Amount to be paid to each such holder is otherwise entitled to receive.

Liquidation Event means any liquidation, dissolution, winding up, merger, acquisition, consolidation, issuance or transfer of equity securities or other transaction or series of transactions which causes the then members of the Company to lose controlling or majority voting rights in the Company or the surviving person (if not the Company), or any transaction or series of transactions in which all or substantially all assets including intellectual property of the Company are disposed via sale, lease or other arrangement, or the grant of an exclusive license to all or substantially all of the Company’s intellectual property (other than to one or more wholly-owned subsidiaries of the Company).

(e)

Voting rights

Holders of the Preferred Shares are entitled to the number of votes equal to the number of ordinary shares into which the Preferred Shares are convertible. Except as otherwise required by law, the holders of ordinary shares, as such, shall not be entitled to vote on any amendment to the articles of the Company that relates solely to the rights, preferences, privileges and restrictions of the Preferred Shares, if the holders of the Preferred Shares, as applicable, are entitled to vote thereon as a separate class pursuant to the articles of the Company or pursuant to applicable law.

Presentation and Classification

The Company elected to designate the Preferred Shares as financial liabilities at FVTPL as a whole. The fair value change of the Preferred Shares is charged/credited to fair value change of Preferred Shares in profit or loss except for the portion attributable to credit risk change which shall be charged/credited to other comprehensive income, if any. The fair value change recognized in profit or loss includes any interest paid, if any, on the financial liabilities. The management of the Company considered that there is insignificant credit risk change on the financial liabilities that drives the fair value change of the Preferred Shares during the years ended December 31, 2021, 2022 and 2023.

The movement of the Preferred Shares at the end of each reporting period is as follows:


	Preferred shares
As of January 1, 2021	$	284,791
Change in fair value		37,424
As of December 31, 2021		322,215
Change in fair value		189,646
As of December 31, 2022		511,861
Change in fair value		76,424
Conversion of convertible preferred shares into post-closing ordinary shares		(588,285	)
As of December 31, 2023	$	—

The Preferred Shares were valued by the management of the Company with reference to valuations carried out by an independent qualified professional valuer not connected with the Group, which has appropriate qualifications and experiences in valuation of similar instruments.

The Company used the Black-Scholes model to determine the underlying share value of the Company and performed an equity allocation based on option pricing model (the “OPM” model) to arrive the fair value of the Preferred Shares at the end of each reporting period.

In addition to the underlying share value of the Company determined by Black-Scholes model, other key valuation assumptions used in the OPM model to determine the fair value of the Preferred Shares are as follows:


	2021			2022
Time to liquidation	1.5 years			1.25 years
Risk-free rate		0.56	%		4.65	%
Expected volatility (note)		72.5	%		75	%
Dividend yield		0	%		0	%
Possibility under IPO scenario		25	%		85	%
Possibility under liquidation scenario		75	%		15	%

Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies.

On March 29, 2023, all the preferred shares were converted into common shares, and therefore as of December 31, 2023, there were no longer any preferred shares.

Other Payables and Accruals - Summary of Other Payables and Accruals (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Other Payables And Accruals [Abstract]
Payables in respect of research and development expenses	$ 4,471	$ 5,435
Accrued salaries and bonuses	2,166	2,475
Accrued other expenses	1,025	1,662
Deposit received for a potential out-licensing drug patent (note)	1,000	1,000
Other payables	500	1,103
Total	$ 9,162	$ 11,675

Share Capital/Treasury Shares - Summary of Share Capital (Parenthetical) (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [line items]
Proceeds from exercise of options	$ 85	$ 392	$ 141
Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares	62,443	8,552,187	6,511,135
Share based compensation by share based award share options excercised weighted average exercise price		$ 0.046	$ 0.022
Business Combination [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares		613,013	466,712
Number of shares issued and fully paid exchange ratio pursuant to business combination		0.071679	0.071679
Exercise Price One [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares	38,893	498,958	6,004,989
Share based compensation by share based award share options excercised weighted average exercise price	$ 0.28	$ 0.01	$ 0.01
Exercise Price One [Member] \| Business Combination [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares		35,765	430,432
Share based compensation by share based award share options excercised weighted average exercise price		$ 0.14	$ 0.14
Exercise Price Two [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares	16,202	7,088,541	134,375
Share based compensation by share based award share options excercised weighted average exercise price	$ 2.93	$ 0.02	$ 0.02
Exercise Price Two [Member] \| Business Combination [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares		508,100	9,632
Share based compensation by share based award share options excercised weighted average exercise price		$ 0.28	$ 0.28
Exercise Price Three [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares	4,122	101,146	371,771
Share based compensation by share based award share options excercised weighted average exercise price	$ 3.63	$ 0.21	$ 0.21
Exercise Price Three [Member] \| Business Combination [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares		7,250	26,648
Share based compensation by share based award share options excercised weighted average exercise price		$ 2.93	$ 2.93
Exercise Price Four [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares	3,226	863,542
Share based compensation by share based award share options excercised weighted average exercise price	$ 4.32	$ 0.26
Exercise Price Four [Member] \| Business Combination [Member] \| Two Thousand and Sixteen Plan [Member]
Disclosure of classes of share capital [line items]
Stock issued during the period exercise of stock options shares		61,898
Share based compensation by share based award share options excercised weighted average exercise price		$ 3.63

Other Gains and Losses (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of Other Gains and Losses [Abstract]

Summary of Information about Other Gains and Losses


	Years ended December 31,
	2021		2022			2023
Exchange gains (losses), net	$	36	$	(829	)	$	1,191

Restricted Net Assets - Additional information (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
China [Member]
Disclosure In Entirety Of Restricted Assets [Line Items]
Restricted net assets	$ 52,298	$ 35,000

Major Non-Cash Transactions - Additional Information (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021
Disclosure of Major Non-Cash Transactions [Line Items]
Right-of-use assets	$ 425,000	$ 991,000
Lease liabilities	425,000	991,000
Treasury shares		68,000	$ 1,647,000	$ 3,252,000
Non Cash Transaction [Member]
Disclosure of Major Non-Cash Transactions [Line Items]
Right-of-use assets	0	548,000	53,000
Treasury Shares [Member] \| Non Cash Transaction [Member]
Disclosure of Major Non-Cash Transactions [Line Items]
Treasury shares	$ 68,000	$ 1,579,000	$ 1,605,000

Share-Based Payment Transactions

12 Months Ended

Dec. 31, 2023

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Share-Based Payment Transactions

27.

SHARE-BASED PAYMENT TRANSACTIONS

On July 19, 2016, the shareholders of the Company approved the adoption of the 2016 equity incentive plans (the “2016 Plan”) for the purpose to secure and retain employees, directors and consultants of the Company (the “Eligible Persons”), provide incentives for them to exert maximum efforts for the success of the Company and any affiliate and provide means by which the Eligible Persons may benefit from increases in value of the ordinary shares of the Company.

The 2016 Plan provides for the grant of the following types of share awards: (i) restricted share awards, (ii) share options, (iii) share appreciation rights, (iv) restricted share unit awards, and (v) other share awards. The overall limit on the number of underlying shares which may be delivered pursuant to all awards granted under the 2016 Plan is 337,225,866 and 337,225,866 ordinary shares of the Company as of December 31, 2022 and 2023, respectively, subject to any adjustments for other dilutive issuances.

In connection with the Business Combination, the Apollomics Board adopted the 2023 Incentive Award Plan (as amended from time to time), which is referred to in this Annual Report as the “2023 Incentive Plan” and became effective as of the Closing. The 2023 Incentive Plan allows us to make equity and equity-based incentive awards to officers, employees, non-employee directors and our consultants and affiliates. Our Board anticipates that providing such persons with a direct stake in us will assure a closer alignment of the interests of such individuals with our interests and the interests of our shareholders, thereby stimulating their efforts on our behalf and strengthening their desire to remain with us and our affiliates.

Restricted share awards

All the restricted shares shall be subject to repurchase at the option by the Company at the subscription price paid by Eligible Persons upon voluntary or involuntary termination of his employment with the Company (the “Repurchase Option”).

The Repurchase Option shall be exercised by the Company and/or the designees of the Company as to the number of unreleased shares, within sixty days after the termination of his employment with the Company giving written notice to Eligible Persons.

The aforesaid arrangement has been accounted for as share-based payment transactions. Accordingly, the Group measured the fair value of the unvested restricted shares as of the grant date and is recognizing the amount as compensation expense over the vesting period for each separately vesting portion of the unvested restricted shares.

The subscription price received by the Group in relation to the unvested restricted shares that are subject to the Repurchase Option held by the Company have been recognized as financial liabilities arising from unvested restricted shares as disclosed in Note 22.

The total expense recognized in the consolidated statements of profit or loss and other comprehensive income for the restricted shares granted are approximately $7 and $39 and nil, for the years ended December 31, 2021, 2022 and 2023, respectively.

The following table summarized the Group’s restricted shares movement during the years ended December 31, 2021, 2022 and 2023:


	2021			2022			2023
	Number of unvested restricted shares			Number of unvested restricted shares			Number of unvested restricted shares
Outstanding at January 1,		14,447,616			8,094,901			6,930,235
Vested		(6,352,715	)		(1,164,666	)		(6,930,235	)
Outstanding at December 31,		8,094,901			6,930,235			—

To present these restricted shares to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these would have been presented as follows:


	2021			2022			2023
	Number of unvested restricted shares			Number of unvested restricted shares			Number of unvested restricted shares
Outstanding at January 1,		1,889,882			1,009,724			496,752
Vested		(880,158	)		(512,972	)		(496,752	)
Outstanding at December 31,		1,009,724			496,752			—

The range of subscription price for the restricted shares is $0.003 to $0.01 per share. The time-based restricted shares shall be entirely vested ratably on a monthly basis over48-monthsvesting period or with 25% be vested on the first anniversary of the vesting inception date and remaining portion vested ratably on a monthly basis over 36-months vesting period. The milestone-based restricted shares will be vested upon achievement of specified performance conditions. The expected vesting period is estimated by the management of the Company based on the most likely outcome of each of the performance condition. During the year ended December 31, 2021, 2022 and 2023, nil, nil, and 496,752 milestone-based restricted shares have been vested, respectively.

Share options

The following table discloses movements of the Company’s share options under the 2016 Plan held by grantees during the years ended December 31, 2021 and 2022:


	2021					2022
	Number of Options			Weighted- average exercise price		Number of Options			Weighted- average exercise price
Outstanding at January 1,		151,133,235		$	0.169		155,059,183		$	0.203
Granted		39,715,000		0.279			11,500,000			0.310
Exercised		(6,511,135	)	0.022			(8,552,187	)	0.046
Forfeited		(29,277,917	)	0.169			(22,027,291	)	0.232
Outstanding at December 31,		155,059,183		0.203			135,979,705		0.217
Exercisable at the end of the year		78,269,054					67,667,737

To present the Company's share options to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these share options would have been presented as follows during the years ended December 31, 2021, 2022 and 2023:


	2021					2022					2023
	Number of Options			Weighted- average exercise price		Number of Options			Weighted- average exercise price		Number of Options			Weighted- average exercise price
Outstanding at January 1,		10,833,079		$	2.358		11,114,486		$	2.832		9,746,889		$	3.027
Options granted		2,846,731		3.892			824,309			4.325		3,048,310			9.927
Exercised		(466,712	)	0.307			(613,012	)	0.642			(62,443	)	1.397
Forfeited		(2,098,612	)	2.238			(1,578,894	)	3.237			(808,341	)		0.570
Outstanding at December 31,		11,114,486		2.832			9,746,889		3.027			11,924,415		4.615
Exercisable at the end of the year		5,610,248					4,850,356					7,859,478

No share options granted in the above table under the 2016 Plan will be exercisable after the expiration of 10 years from the date of its grant.

The share options outstanding as of December 31, 2021, 2022 and 2023 had a weighted average remaining contractual life of 8.2 years, 7.4 years, and 6.25 years, respectively. During the year ended December 31, 2021, 2022 and 2023, the weighted average fair value of the share options granted were $2.28 per share, $0.2035 per share, and $7.13 per share, respectively. The weighted average fair value of the share options granted during the years ended December 31, 2021, and 2022 were presented as $0.16337 per share, and $0.2035 per share, respectively before giving effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679.The time-based share options will be vested ratably on a monthly basis over a range of a 24 month to 48 month vesting period or with 50% or 25% vested on the first anniversary of the vesting inception date and the remaining portion vested ratably on a monthly basis over the remaining 12 months to 36 months vesting period. The milestone-based share options will be vested upon achievement of specified performance conditions. The expected vesting period is estimated by the management of the Company based on the most likely outcome of each of the performance conditions. During the years ended December 31, 2021, 2022, and 2023, of the 853,575 time-based share options had been early exercised by Dr. Yu and subject to the Repurchase Option, the remaining unvested early exercised share options as of December 31, 2021, 2022, and 2023 are 429,490, nil and nil, respectively.

The Option Pricing Model (“OPM”) was used to determine the fair value of the option granted.

The key inputs into the model were as follows:


	Years ended December
	2021			2022			2023
Grant date option fair value per share	$0.1430-0.1544			$0.0933-0.1517			$0.01-0.511
Exercise price	$0.26-0.31			$0.31			$0.07-0.72
Grant date option fair value per share as converted	$1.995-2.154			$1.302-2.116			$0.14-7.127
Exercise price as converted	$3.63-4.32			$4.32			$0.94-10.01
Expected volatility (note i)	75%-80%			75%-77.5%				72.5	%
Expected life	6.078 years			6.078 years			6.250 years
Risk-free rate	0.51%-1.09%			1.35%-3.98%				3.67	%
Expected dividend yield		—	%		—	%		—	%

Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies.

The total expense recognized in the consolidated statements of profit or loss and other comprehensive income for share options and restricted stocks granted under the 2016 and 2023 Plans are approximately $8,115, $3,543, and $12,685, and expenses for consultancy fees of approximately $129, $27, and $19 for the years ended December 31, 2021, 2022 and 2023, respectively.

Restricted stock

There were no restricted stocks issued under the 2016 Plan during the years ended December 31, 2021 and 2022. Under the 2023 Plan, the following table discloses movements of the Company’s restricted stocks under the 2023 Plan for the year December 31, 2023.


	Year ended December 31, 2023
	Number of restricted stocks		Weighted- average exercise price
Outstanding at January 1, 2023		—	$	—
Restricted stock granted		207,945	$	5.410
Outstanding at December 31, 2023		207,945	$	5.410
Exercisable at the end of the year		—

Income Tax Expenses

12 Months Ended

Dec. 31, 2023

Disclosure of Income Tax [Abstract]

Income Tax Expenses

11.

INCOME TAX EXPENSES

The Company is exempted from taxation under the laws of the Cayman Islands.

The US Corporate Income Tax (“CIT”) includes (a) federal income tax calculated at a flat rate of 21% on the US federal taxable income in accordance to the Tax Cuts and Jobs Act of 2017; (b) state income tax is calculated based on the federal taxable income with state tax adjustments, which is then allocated or apportioned to the respective state (i.e. percentage of taxable income that should be apportioned or specially allocated to the respective states in which the Group operates) based on the apportionment factors provided from the state tax returns in previous year, and (c) state minimum tax if there is no assessable profit.

The PRC enterprises income tax (“EIT”) is calculated at the prevailing tax rate on the taxable income of the subsidiaries operating in the PRC. Under the Law of the PRC on EIT (the “EIT Law”) and Implementation Regulation of the EIT Law, the applicable tax rate of the PRC subsidiaries is at 25% during the years ended December 31, 2021, 2022 and 2023.

Under the Treasury Law Amendment (Enterprise Tax Plan Base Rate Entities) Bill 2018 of Australia, qualifying base rate entities that meet aggregate turnover threshold can be eligible for a lower corporate tax rate. Upon assessment on the base rate entity qualification on an ongoing basis, Apollomics (Australia) Pty. Ltd., a wholly-owned subsidiary of the Company, applies a corporate tax rate of 26%, 25% and 25% for the years ended December 31, 2021, 2022 and 2023, respectively.

Hong Kong Profits Tax is calculated at 16.5% of the estimated assessable profit for a Hong Kong incorporated subsidiary.


	Years ended December 31,
	2021		2022		2023
US CIT
— current year	$	1	$	1	$	10
— over-provision in respect of prior years		—		—		—
Deferred tax (Note 18)		—		—		—
	$	1	$	1	$	10

Other than the subsidiary operating in the US, no provision for income taxation has been made as the Company and the other subsidiaries either had no assessable profit or incurred tax losses in the PRC, Australia and Hong Kong for the years ended December 31, 2021, 2022 and 2023.

The income tax (credit) expense for the years ended December 31, 2021, 2022 and 2023 can be reconciled to the loss before taxation per the consolidated statements of profit or loss and other comprehensive income as follows:


	Years ended December 31,
	2021			2022			2023
Loss before taxation	$	(94,796	)	(240,810			$	(172,591	)
Tax at the US federal tax rate of 21%		(19,907	)		(50,570	)		(36,244	)
Tax effect of expenses not deductible for tax purpose		20,419			45,739			568
Tax effect of income not taxable for tax purpose		(309	)		(257	)		—
Tax effect of additional qualified expenses deductible for tax purpose (note)		—			(1,517	)		(741	)
Tax effect of R&D Credits		—			—			(2,311	)
Tax effect of tax losses not recognized		360			7,027			10,277
Tax effect of foreign tax differential rates		(562	)		(421	)		28,461
Income tax expense for the year	$	1		$	1		$	10

Note: The amount represents additional 75% income tax deduction in respect of qualifying research and development expenditures incurred for the year.

Convertible Preferred Shares (Tables)

12 Months Ended

Dec. 31, 2023

Convertible Preferred Shares [Abstract]

Disclosure of Preferred Shares Issued Pursuant to Subscription Agreement

The Company entered into preferred share subscription agreements with several independent investors and the details of issued preferred shares (the “Preferred Shares”) are set out as follows:


	Date of issue	Total number of Preferred Shares issue		Subscription price per share		Subscription price total
	July 26, 2016 to
Series A1 Preferred Shares	July 28, 2016		88,038,389	$	0.04543	$	4,000
	January 31, 2019		44,019,194		0.04543		2,000
			132,057,583				6,000
Series A2 Preferred Shares	July 21, 2017 to
	July 25, 2017		73,371,157		0.05111		3,750
	September 19, 2018 to
Series B Preferred Shares	December 27, 2018		260,709,579		0.3329		86,800
	January 8, 2019 to
	March 25, 2019		36,643,370		0.3329		12,200
			297,352,949				99,000
	September 10, 2020 to
Series C Preferred Shares	September 30, 2020		141,692,465		0.4845		68,650
	October 5, 2020 to
	November 5, 2020		114,757,479		0.4845		55,600
			256,449,944				124,250

The exchange ratio has been applied to these preferred shares to give effect to the Business Combination of March 29, 2023 and these would have been as follows:


	Date of issue	Total number of Preferred Shares issue		Subscription price per share		Subscription price total
	July 26, 2016 to
Series A1 Preferred Shares	July 28, 2016		6,310,503	$	0.6338	$	4,000
	January 31, 2019		3,155,252		0.6338		2,000
			9,465,755				6,000
Series A2 Preferred Shares	July 21, 2017 to
	July 25, 2017		5,259,170		0.7130		3,750

	September 19, 2018 to
Series B Preferred Shares	December 27, 2018		18,687,400		4.6443		86,800
	January 8, 2019 to
	March 25, 2019		2,626,559		4.6443		12,200
			21,313,959				99,000

	September 10, 2020 to
Series C Preferred Shares	September 30, 2020		10,156,372		6.7593		68,650
	October 5, 2020 to
	November 5, 2020		8,225,701		6.7593		55,600
			18,382,073				124,250

Disclosure of Movement in Preference Shares at End of Each Reporting Period

The movement of the Preferred Shares at the end of each reporting period is as follows:


	Preferred shares
As of January 1, 2021	$	284,791
Change in fair value		37,424
As of December 31, 2021		322,215
Change in fair value		189,646
As of December 31, 2022		511,861
Change in fair value		76,424
Conversion of convertible preferred shares into post-closing ordinary shares		(588,285	)
As of December 31, 2023	$	—

Disclosure of Significant Unobservable Inputs Used in Measuring the Fair Value of Convertible Preferred Shares


	2021			2022
Time to liquidation	1.5 years			1.25 years
Risk-free rate		0.56	%		4.65	%
Expected volatility (note)		72.5	%		75	%
Dividend yield		0	%		0	%
Possibility under IPO scenario		25	%		85	%
Possibility under liquidation scenario		75	%		15	%

Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies.

On March 29, 2023, all the preferred shares were converted into common shares, and therefore as of December 31, 2023, there were no longer any preferred shares.

Consolidated Statements of Changes in Shareholders' Equity Deficit (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Mar. 28, 2023	Dec. 31, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accumulated losses		$ (646,965)	$ (646,965)	$ (474,600)
Maxpro Capital Acquisition Corp. [Member]
Decrease in share premium due to reclassification of warrants from equity to liabilities			7,100
Increase of warrant liability due to recalcification from equity			1,300
Decrease in accumulated losses due to reclassification of warrants from equity to liabilities			5,800
Accumulated losses		$ (5,800)	(5,800)
Net impact of equity by reduction of premium due to recalcification of warrants			$ 1,300
Preclosing Apollomics Ordinary Shares [Member]
Exercise of share options	435,833			8,552,187	6,511,135
Post-Closing Apollomics Ordinary Shares [Member]
Number of ordinary shares issued in exchange of pre closing business combination ordinary shares			31,241	613,012	466,712
Stock issued during the period exercise of stock options shares		31,202	62,443

Other Payables And Accruals - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure Of Other Payables And Accruals [Abstract]
Current deposits from customers	$ 1,000	$ 1,000

Lease Liabilities (Tables)

12 Months Ended

Dec. 31, 2023

Lease liabilities [abstract]

Summary of Detailed Information About Contractual Maturities of Lease Liabilities


	As of December 31,
	2022			2023
Lease liabilities payable:
Within one year	$	614		$	158
More than one year, but not exceeding two years		126			126
More than two years, but not exceeding five years		251			141
		991			425
Less: Amount due for settlement within 12 months shown under current liabilities		(614	)		(158	)
Amount due for settlement after 12 months shown under non-current liabilities	$	377		$	267

Loss Per Share - Disclosure of Detailed Information about Anti Dilutive Securities Excluded from Computation of Diluted Loss Per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Series A1 Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		132,057,583	132,057,583
Series A2 Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		73,371,157	73,371,157
Series B Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		297,352,949	297,352,949
Series C Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		256,449,944	256,449,944
Exchange Ratio of 0.071679 [Member] \| Series A1 Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		9,465,754	9,465,754
Exchange Ratio of 0.071679 [Member] \| Series A2 Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		5,259,170	5,259,170
Exchange Ratio of 0.071679 [Member] \| Series B Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		21,313,959	21,313,959
Exchange Ratio of 0.071679 [Member] \| Series C Preferred Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		18,382,073	18,382,073
Unvested Restricted Shares [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		6,930,235	8,094,901
Unvested Restricted Shares [Member] \| Exchange Ratio of 0.071679 [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount		496,752	580,234
Share Options [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	12,132,460	135,979,705	155,059,183
Share Options [Member] \| Exchange Ratio of 0.071679 [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	12,132,460	9,746,889	11,114,487
Apollomics Private Warrants [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	619,400
Apollomics Private Warrants [Member] \| Exchange Ratio of 0.071679 [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	619,400
Apollomics Public Warrants [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	10,350,000
Apollomics Public Warrants [Member] \| Exchange Ratio of 0.071679 [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	10,350,000
Penny Warrants [Member]
Earnings per share [line items]
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount	57,500

Schedule I - Additional Financial Information of Parent Company

12 Months Ended

Dec. 31, 2023

Additional information [abstract]

Schedule I - Additional Financial Information of Parent Company

Schedule I - Additional financial information of parent company

APOLLOMICS INC.

Condensed Statement of Loss and Other Comprehensive Loss

(All amounts in thousands of $)


	Years ended December 31,
	2021			2022			2023
Other income	$	42		$	112		$	49
Fair value change of financial assets at FVTPL		2			323			821
Fair value change of financial liabilities at FVTPL		—			—			1,597
Fair value change of convertible preferred shares		(37,424	)		(189,646	)		(76,430	)
Research and development expenses		(2,643	)		(992	)		(7,772	)
Administrative expenses		(4,494	)		(1,982	)		(13,215	)
Finance costs		—			—			(28	)
Other expense		(4,522	)		(5,532	)		(46,003	)
Share of loss in subsidiaries		(45,757	)		(43,094	)		(31,610	)
Loss before taxation		(94,796	)		(240,811	)		(172,591	)
Income tax expense		—			—			(10	)
Loss and total comprehensive loss for the year, attributable to owners of the Company	$	(94,796	)	$	(240,811	)	$	(172,601	)

Schedule I - Additional financial information of parent company

APOLLOMICS INC.

Condensed Statements of Financial Position

(All amounts in thousands of $)


	As of December 31,
	2022			2023
Non-current assets
Intangible assets	$	1,778		$	1,759
Amount due from subsidiaries		70,560			70,103
Total non-current assets		72,338			71,862
Current assets
Deposits, prepayments and deferred expenses		—			630
Financial assets at FVTPL		19,067			5,761
Cash and cash equivalents		6,001			2,330
Total current assets		25,068			8,721
Total assets		97,406			80,583
Current liabilities
Other payables and accruals		2,986			366
Financial liabilities arising from unvested restricted shares		68			—
Total current liabilities		3,054			366
Net current assets		22,014			8,355
Total assets less current liabilities		94,352			80,217
Non-current liabilities
Convertible preferred shares		511,861			—
Warrant liabilities	—				330
Deficit in subsidiaries		30,611			38,653
Total non-current liabilities		542,472			38,983
Net assets (liabilities)	$	(448,120	)	$	41,234
Equity
Share capital		41			9
Treasury shares		(68	)		—
Share premium		12,279			661,474
Reserves		14,228			26,716
Accumulated losses		(474,600	)		(646,965	)
	$	(448,120	)	$	41,234

Schedule I - Additional financial information of parent company

APOLLOMICS INC.

Condensed Statements of Cash Flows

(All amounts in thousands of $)


	Years ended December 31,
	2021			2022			2023
OPERATING ACTIVITIES
Loss before taxation	$	(94,796	)	$	(240,811	)	$	(172,591	)
Adjustments for:
Share of loss in subsidiaries		45,757			43,094			31,610
Interest income		(42	)		(112	)		(49	)
Amortization of intangible assets		20			20			20
Fair value change of financial assets at FVTPL		(2	)		(323	)		(821	)
Fair value change of financial liabilities at FVTPL		—			—			(1,597	)
Fair value change of convertible preferred shares		37,424			189,646			76,430
IFRS 2 listing expense		—			—			45,524
Portion of PIPE issuance costs allocated to PIPE warrants		—			—			38
Share-based payment expenses		4,056			818			12,685
Non-cash adjustments to other expenses		—			(2,563	)		2,484
Operating cash flows before movements in working capital		(7,583	)		(10,231	)		(6,267	)
(Increase)/decrease in deposits, prepayments and deferred expenses		162			2,812			(630	)
Increase/(decrease) in other payables and accruals		1,119			859			(2,620	)
NET CASH USED IN OPERATIONS		(6,302	)		(6,560	)		(9,517	)
Taxation paid		—			—			(10	)
NET CASH USED IN OPERATING ACTIVITIES		(6,302	)		(6,560	)		(9,527	)
INVESTING ACTIVITIES
Interest received		42			112			49
Investment in subsidiaries		(27,150	)		(25,926	)		(8,042	)
Advance to subsidiaries		(4,818	)		(2,013	)		—
Repayment from subsidiaries		—			2,135			457
Purchase of intangible assets		(1,500	)		—			—
Proceeds from disposal of financial asset at FVTPL		—			5,000			13,307
NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES		(33,426	)		(20,692	)		5,771
FINANCING ACTIVITIES
Proceeds on issue of convertible preferred shares		—			—			—
Proceeds from issue of shares upon exercise of share options		141			392			85
Accrued issuance costs paid		(1,173	)		—			—
NET CASH FROM (USED IN) FINANCING ACTIVITIES		(1,032	)		392			85
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		(40,760	)		(26,860	)		(3,671	)
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR		73,621			32,861			6,001
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	$	32,861		$	6,001		$	2,330

Schedule I - Additional financial information of parent company

APOLLOMICS INC.

Notes to the condensed Financial Information of Parent Company

1. Schedule I has been provided pursuant to the requirements of Rule12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year.

2. The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. For the purpose of this Schedule I, Apollomics Inc., as the parent company, records its investments in subsidiaries under the equity method of accounting in accordance with International Accounting Standards 27 Separate Financial Statements, as issued by the International Accounting Standards Board. Such investments are presented on the Condensed Statements of Financial Position as “Investment in subsidiaries”. Ordinarily under the equity, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduce to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries in investment in subsidiaries regardless of the carrying value of the investment in subsidiaries even though the parent company is not obligated to provide continuing support or fund losses. The excess amount is recorded as “Deficit in subsidiaries” on the Condensed Statements of Financial Position.

3. Certain information and footnote disclosures normally included in financial statements prepared in accordance with IFRSs have been condensed or omitted. The footnote disclosures provide certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the accompanying consolidated financial statements.

4. As of December 31, 2022 and 2023, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or guarantees of Apollomics Inc.

Lease Liabilities

12 Months Ended

Dec. 31, 2023

Lease liabilities [abstract]

Lease Liabilities

24.

LEASE LIABILITIES


	As of December 31,
	2022			2023
Lease liabilities payable:
Within one year	$	614		$	158
More than one year, but not exceeding two years		126			126
More than two years, but not exceeding five years		251			141
		991			425
Less: Amount due for settlement within 12 months shown under current liabilities		(614	)		(158	)
Amount due for settlement after 12 months shown under non-current liabilities	$	377		$	267

The Group leased various offices, and plant and equipment as disclosed in Note 15 for its administration, and research and development activities. These lease liabilities were measured at the present value of the lease payments that are not yet paid.

The Group does not face a significant liquidity risk with regard to its lease liabilities.

The lease agreements did not contain any contingent rent nor any purchase option for the leases.

The weighted average incremental borrowing rates applied to lease liabilities range from 4.75% to 6.00% during the years ended December 31, 2022 and 2023.

Other Payables and Accruals

12 Months Ended

Dec. 31, 2023

Disclosure Of Other Payables And Accruals [Abstract]

Other Payables and Accruals

22.

OTHER PAYABLES AND ACCRUALS


	As of December 31,
	2022		2023
Payables in respect of research and development expenses	$	5,435	$	4,471
Accrued salaries and bonuses		2,475		2,166
Accrued other expenses		1,662		1,025
Deposit received for a potential out-licensing drug patent (note)		1,000		1,000
Other payables		1,103		500
	$	11,675	$	9,162

Note: During the year ended December 31, 2020, the Group signed an exclusive right of negotiation agreement with an independent third party (the “Independent Third Party”) to negotiate out-licensing a drug patent to the Independent Third Party. Under the exclusive right of negotiation agreement, we received a deposit of $1,000 which may be considered as consideration for the exclusive right of negotiation if the Independent Third Party has not identified any negative findings (as stated in the exclusive right of negotiation agreement) by March 2, 2021. As of the date of this report, despite no negative findings have been identified, we considered the negotiation will not proceed further, and the Independent Third Party has not requested a refund of the balance.

Basis of Preparation of the Consolidated Financial Statements

12 Months Ended

Dec. 31, 2023

Disclosure of Basis of Preparation of Financial Statements Explanatory [Abstract]

Basis of Preparation of the Consolidated Financial Statements

BASIS OF PREPARATION OF THE CONSOLIDATED FINANCIAL STATEMENTS

The consolidated financial statements have been prepared based on the accounting policies set out in Note 4 which conform with International Financial Reporting Standards (“IFRSs”) as issued by the International Accounting Standards Board (“IASB”).

The Group has incurred recurring losses and negative cash flows from operations since inception and had an accumulated loss of $646,965 as of December 31, 2023. The Group recorded net assets of $41,234 as of December 31, 2023. The Group regularly monitors its current and expected liquidity requirements and, as needed, updates its operating plans, to ensure that it maintains sufficient cash balances to meet its liquidity requirements in the short and long term.

Based upon our 2024 operating plan, and our balance of cash, cash equivalents, and a federal money market fund of $37.8 million as of December 31, 2023, we estimate that we will have sufficient liquidity to continue as a going concern through at least December 31, 2024. We will require additional capital, from equity, debt or strategic partnerships, to continue as a going concern in

the future. It is uncertain whether such capital will be available in amounts or on terms acceptable to us, if at all. If we are not able to obtain additional capital to meet our cash requirements in the future, our business, financial condition, results of operations and prospects could be materially and adversely affected. There can be no assurance that management’s attempts to raise additional capital will be successful, and could ultimately result in reassessing the Company’s ability to continue as a going concern.

Share Capital/Treasury Shares - Summary of Share Capital (Detail) - USD ($)

12 Months Ended

Jan. 01, 2022

Jan. 01, 2021

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Disclosure of classes of share capital [line items]

Exercise of share options, Value

$ 85,000

^[1]

$ 391,000

^[2]

$ 140,000

^[3]

Ordinary Shares [Member]

Disclosure of classes of share capital [line items]

Number of shares authorised

444,343,488

Value of shares authorized

Number of shares issued and fully paid

386,741,005

401,804,327

393,252,140

Value of shares issued and fully paid

$ 39,000

$ 41,000

$ 40,000

Exercise of share options, Shares

8,552,187

6,511,135

Exercise of share options, Value

$ 0.0001

$ 1,000

Ordinary Shares [Member] | Business combinations [member]

Disclosure of classes of share capital [line items]

Number of shares authorised

600,000,000

Value of shares authorized

Number of shares issued and fully paid

89,495,790

28,800,926

28,187,914

27,721,202

Value of shares issued and fully paid

$ 9

$ 3

Exercise of share options, Shares

62,443

613,012

466,712

Business combination, net of redemptions

$ 0.0001

3,312,715

Post-Closing Apollomics Ordinary Shares [Member] | Business combinations [member]

Disclosure of classes of share capital [line items]

Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares

$ 0.0001

54,420,956

Value of conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares

$ 6

Post-closing Apollomics Class B Ordinary Shares [Member] | Business combinations [member]

Disclosure of classes of share capital [line items]

Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs

$ 0.0001

230,000

post-closing Apollomics Series A Preferred Shares [Member] | Business combinations [member]

Disclosure of classes of share capital [line items]

Issuance of post-closing Apollomics Class A Ordinary Shares upon the conversion of post-closing Apollomics Series A Preferred Shares

$ 0.0001

2,668,750

[1]	The total number of shares issued from the exercise of stock options consisted of the issuance of 435,833 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2023 to March 28, 2023. These Pre-Closing Apollomics Ordinary Shares were exchanged for 31,241 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 31,202 Post-Closing Apollomics Ordinary Shares between March 29, 2023 to December 31, 2023, totaling 62,443 exercise of stock options for the year ended December 31, 2023.
[2]	The total number of shares issued from the exercise of stock options consisted of the issuance of 8,552,187 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2022 to December 31, 2022. These Pre-Closing Apollomics Ordinary Shares were exchanged for 613,012 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination.
[3]	The total number of shares issued from the exercise of stock options consisted of the issuance of 6,511,135 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2021 to December 31, 2021. These Pre-Closing Apollomics Ordinary Shares were exchanged for 466,712 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination.

Share Capital/Treasury Shares - Summary of Treasury Shares (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Treasury Shares [Line Items]
Number of treasury shares, Beginning	6,930,235	14,086,748	26,365,915
Treasury shares value, Beginning	$ 68,000	$ 1,647,000
Restricted shares vested		(1,164,666)	(6,352,715)
Restricted shares vested, subscription price per share		$ 0.01	$ 0.01
Restricted shares vested, value		$ (21,000)	$ (64,000)
Early exercised share options vested	(6,930,235)	(5,991,847)	(5,926,452)
Early exercised share options vested, subscription price per share	$ 0.26	$ 0.26	$ 0.26
Early exercised share options vested, value	$ (68)	$ (1,558,000)	$ (1,541,000)
Number of treasury shares, Ending		6,930,235	14,086,748
Treasury shares value, Beginning		$ 68,000	$ 1,647,000
Maxpro Capital Acquisition Corp. [Member]
Disclosure Of Treasury Shares [Line Items]
Number of treasury shares, Beginning	496,752	1,009,724	1,889,882
Treasury shares value, Beginning	$ 68,000	$ 1,647,000	$ 3,252,000
Restricted shares vested		(83,482)	(455,356)
Restricted shares vested, subscription price per share		$ 0.14	$ 0.14
Restricted shares vested, value		$ (21,000)	$ (64,000)
Early exercised share options vested	(496,752)	(429,490)	(424,802)
Early exercised share options vested, subscription price per share	$ 3.63	$ 3.63	$ 3.63
Early exercised share options vested, value	$ (68,000)	$ (1,558,000)	$ (1,541,000)
Number of treasury shares, Ending		496,752	1,009,724
Treasury shares value, Beginning		$ 68,000	$ 1,647,000

Share Capital/Treasury Shares (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of classes of share capital [abstract]

Summary of Share Capital

Share capital

The share capital as of December 31, 2021 and 2022 represented the issued ordinary share capital of the Company.


		Number of		Par value
	Notes	shares		per share		Amount
Authorized:
As of January 1, 2021, December 31, 2021 and 2022			444,343,488			$	44
Issued and fully paid:
As of January 1, 2021			386,741,005				39
Exercise of share options vested	(i)		6,511,135	$	0.0001		1
As of December 31, 2021			393,252,140				40
Exercise of share options vested	(ii)		8,552,187		0.0001		1
As of December 31, 2022			401,804,327				41


		Number of		Par value
	Notes	shares		per share		Amount
Authorized:
As of December 31, 2023			600,000,000			$	3
Issued and fully paid:
As of January 1, 2021			27,721,202				3
Exercise of share options	(i)		466,712	$	0.0001		—
As of December 31, 2021			28,187,914				3
Exercise of share options vested	(ii)		613,012		0.0001		—
As of December 31, 2022			28,800,926				3
Exercise of share options vested	(iii)		62,443		0.0001
Business combination, net of redemptions			3,312,715		0.0001
Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares			54,420,956		0.0001		6
Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs			230,000		0.0001
Issuance of post-closing Apollomics Class A Ordinary Shares upon the conversion of post-closing Apollomics Series A Preferred Shares			2,668,750		0.0001
As of December 31, 2023			89,495,790				9

All the ordinary shares and restricted shares issued during the years ended December 31, 2021, 2022 and 2023 rank pari passu with the existing shares in all respects.

Notes:

(i)

(ii)

(iii)

Summary of Treasury Shares

Treasury shares


	Number of			Subscription
	treasury			price per
	shares			share		Amount
As of January 1, 2021		26,365,915				$	3,252
Restricted shares vested		(6,352,715	)	$	0.01		(64	)
Early exercised share options vested		(5,926,452	)		0.26		(1,541	)
As of December 31, 2021		14,086,748					1,647
Restricted shares vested		(1,164,666	)		0.01		(21	)
Early exercised share options vested		(5,991,847	)		0.26		(1,558	)
As of December 31, 2022		6,930,235					68
Early exercised share options vested		(6,930,235	)		0.26		(68	)
As of December 31, 2023		—					—

To present these treasury shares to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these would have been presented as follows:


	Number of			Subscription
	treasury			price per
	shares			share		Amount
As of January 1, 2021		1,889,882				$	3,252
Restricted shares vested		(455,356	)	$	0.14		(64	)
Early exercised share options vested		(424,802	)		3.63		(1,541	)
As of December 31, 2021		1,009,724					1,647
Restricted shares vested		(83,482	)		0.14		(21	)
Early exercised share options vested		(429,490	)		3.63		(1,558	)
As of December 31, 2022		496,752					68
Early exercised share options vested		(496,752	)		3.63		(68	)
As of December 31, 2023		—					—

Financial Liabilities Arising from Unvested Restricted Shares

12 Months Ended

Dec. 31, 2023

Disclosure of financial liabilities [abstract]

Financial Liabilities Arising from Unvested Restricted Shares

23.

FINANCIAL LIABILITIES ARISING FROM UNVESTED RESTRICTED SHARES


	As of December 31,
	2022		2023
Payables in respect of unvested restricted shares attributable to:
Dr. Yu (the chief executive of the Company)	$	68	$	—

The amounts represented the repurchase option held by the Company in relation to (i) the unvested restricted shares granted to directors and an employee of the Company; and (ii) the unvested restricted shares issued to a director of the Company who was the

share option holder and had elected to early exercise the share options during the vesting period. Details of the restricted share award and share options are set out in Note 26.

Loss Per Share - Additional Information (Detail) - $ / shares shares in Thousands			12 Months Ended
	Mar. 29, 2023	Mar. 28, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Earnings per share [line items]
Weighted average number of common shares outstanding - Basic	404,186		74,411	28,528	28,107
Weighted average number of common shares outstanding - Diluted	390,944		74,411	28,528	28,107
Total basic earnings (loss) per share		$ (0.23)	$ (2.32)	$ (8.44)	$ (3.37)
Total diluted earnings (loss) per share		$ (0.62)	$ (2.32)	$ (8.44)	$ (3.37)

Convertible Preferred Shares - Disclosure of Movement in Preference Shares at End of Each Reporting Period (Detail) - Series C Preferred Shares [Member] - Preferred Shares [Member] - Level 3 Fair Value [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Movement in Preference Shares at End of Each Reporting Period [Line Items]
Beginning Balance	$ 511,861	$ 322,215	$ 284,791
Change in fair value	76,424	189,646	37,424
Conversion of convertible preferred shares into post-closing ordinary shares	$ (588,285)
Ending Balance		$ 511,861	$ 322,215

Plant and Equipment

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about property, plant and equipment [abstract]

Plant and Equipment

15.

PLANT AND EQUIPMENT


	Leasehold improvements			Furniture and other equipment			Total
COST
As of January 1, 2022	$	135		$	426		$	561
Additions		—			367			367
As of December 31, 2022		135			793			928
Additions		—			—			—
Disposals		—			(363	)		(363	)
As of December 31, 2023		135			430			565
ACCUMULATED DEPRECIATION
As of January 1, 2022		(80	)		(201	)		(281	)
Provided for the year		(34	)		(128	)		(162	)
As of December 31, 2022		(114	)		(329	)		(443	)
Accumulated depreciation removal for disposals		—			75			75
Provided for the year		(18	)		(18	)		(36	)
As of December 31, 2023		(132	)		(272	)		(404	)
CARRYING VALUES
As of December 31, 2022	$	21		$	464		$	485
As of December 31, 2023	$	3		$	158		$	161

The above items of plant and equipment are depreciated over their estimated useful lives between 3 to 5 years, using straight-line method after taking into account the residual values, at the following rates per annum:


Leasehold improvements		Over the shorter of the relevant lease term or 20%
Furniture and other equipment		14% - 33%

Loss Per Share

12 Months Ended

Dec. 31, 2023

Earnings per share [abstract]

Loss Per Share

14.

LOSS PER SHARE

The calculations of the basic and diluted loss per share are based on the following data:


	Years ended December 31,
	2021			2022			2023
Loss:
Loss for the year attributable to owners of the Company for the purpose of calculating basic and diluted loss per share	$	(94,797	)	$	(240,811	)	$	(172,601	)
Number of shares (‘000):
Weighted average number of ordinary shares for the purpose of calculating basic and diluted loss per share		28,107			28,528			74,411
Loss per share – Basic and diluted $	$	(3.37	)	$	(8.44	)	$	(2.32	)

The exchange ratio has been applied to the weighted average number of ordinary shares for the purpose of calculating basic and diluted loss per share shown as 28,107 and 28,528 for the years ended December 2021 and 2022 to give effect to the Business Combination of March 29, 2023, which were 404,186 and 390,944, respectively and the loss per share - basic and diluted shown as ($3.37) and ($8.44) were ($0.23) and ($0.62), respectively, prior to the Business Combination.

The diluted loss per share for the years ended December 31, 2021, 2022 and 2023 does not include the effect of the following instruments held as of December 31, 2021, 2022 and 2023 as their inclusion would be anti-dilutive. As of December 31, 2021 and 2022, Series A1, A2, B and C convertible preferred shares, unvested restricted shares and share options outstanding were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. As of December 31, 2023 share options outstanding and the private and public warrants were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive.


	As of December 31,
	2021 (Note i)		2022 (Note i)		2023 (Note i)
Number of series A1 convertible preferred shares (“Series A1 Preferred Shares”)		9,465,754		9,465,754		—
Number of series A2 convertible preferred shares (“Series A2 Preferred Shares”)		5,259,170		5,259,170		—
Number of series B convertible preferred shares (“Series B Preferred Shares”)		21,313,959		21,313,959		—
Number of series C convertible preferred shares (“Series C Preferred Shares”)		18,382,073		18,382,073		—
Unvested restricted shares		580,234		496,752		—
Share options		11,114,487		9,746,889		12,132,460
Apollomics private warrants		—		—		619,400
Apollomics public warrants		—		—		10,350,000

Note i: The exchange ratio has been applied to these instruments to give effect to the Business Combination


	As of December 31,
	2021 (Note ii)		2022 (Note ii)		2023
Number of series A1 convertible preferred shares (“Series A1 Preferred Shares”)		132,057,583		132,057,583		—
Number of series A2 convertible preferred shares (“Series A2 Preferred Shares”)		73,371,157		73,371,157		—
Number of series B convertible preferred shares (“Series B Preferred Shares”)		297,352,949		297,352,949		—
Number of series C convertible preferred shares (“Series C Preferred Shares”)		256,449,944		256,449,944		—
Unvested restricted shares		8,094,901		6,930,235		—
Share options		155,059,183		135,979,705		12,132,460
Apollomics private warrants		—		—		619,400
Apollomics public warrants		—		—		10,350,000
Penny warrants		—		—		57,500

Note ii: This was the presentation of these instruments as of December 31, 2021 and 2022, respectively, prior to the application of the exchange ratio used in the Business Combination

Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	$ 485
Provided for the year	(87)	$ (162)	$ (133)
Ending balance	161	485
Leasehold Improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	21
Ending balance	3	21
Furniture and Other Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	464
Ending balance	158	464
Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	928	561
Additions		367
Disposals	(363)
Ending balance	565	928	561
Gross carrying amount [member] \| Leasehold Improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	135	135
Ending balance	135	135	135
Gross carrying amount [member] \| Furniture and Other Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	793	426
Additions		367
Disposals	(363)
Ending balance	430	793	426
Accumulated depreciation and amortisation [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(443)	(281)
Accumulated depreciation removal for disposals	75
Provided for the year	(36)	(162)
Ending balance	(404)	(443)	(281)
Accumulated depreciation and amortisation [member] \| Leasehold Improvements [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(114)	(80)
Provided for the year	(18)	(34)
Ending balance	(132)	(114)	(80)
Accumulated depreciation and amortisation [member] \| Furniture and Other Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning balance	(329)	(201)
Accumulated depreciation removal for disposals	75
Provided for the year	(18)	(128)
Ending balance	$ (272)	$ (329)	$ (201)

Business Combination - Schedule of Common Stock Outstanding (Detail) - shares	Mar. 29, 2023	Dec. 31, 2022
PIPE Financing and Business Combination [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	57,994,911
Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding		28,800,926
Maxpro Capital Acquisition Corp. [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	10,350,000
Maxpro Capital Acquisition Corp. [Member] \| PIPE Financing and Business Combination [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	57,994,911
Maxpro Capital Acquisition Corp. [Member] \| Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	54,420,956
Class A ordinary Shares [Member] \| Maxpro Capital Acquisition Corp. [Member] \| Class A Common Stock [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	490,025
Class A ordinary Shares [Member] \| Maxpro Capital Acquisition Corp. [Member] \| Class B Common Stock [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	2,587,500
Class A ordinary Shares [Member] \| Maxpro Capital Acquisition Corp. [Member] \| Class A Common Stock Subject to Possible Redemption [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	79,940
Class A ordinary Shares [Member] \| Maxpro Capital Acquisition Corp. [Member] \| Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	31,240
Class A ordinary Shares [Member] \| Maxpro Capital Acquisition Corp. [Member] \| Conversion of Convertible Promissory Note [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	155,250
Class A Ordinary Shares Net of Redemptions [Member] \| Maxpro Capital Acquisition Corp. [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	3,312,715
Class B ordinary Shares [Member] \| Maxpro Capital Acquisition Corp. [Member] \| Pipe Subscription Agreement [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	230,000

Financial Instruments - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about financial instruments [line items]
Net Assets	$ 41,234	$ (448,120)
Convertible Preferred Shares, Carrying Amount		378,332
Financial assets at FVTPL	5,761	19,067
Level 3 of fair value hierarchy [member]
Disclosure of detailed information about financial instruments [line items]
Gains (losses) recognised in profit or loss excluding exchange differences, fair value measurement, liabilities	$ 76,430	189,646	$ 37,424
Convertible Preferred Shares [Member] \| IPO scenario [Member]
Disclosure of detailed information about financial instruments [line items]
Percentage of reasonably possible increase in unobservable input, liabilities	10.00%
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities	$ 41,969	22,166
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities	0	0
Series A Preferred Shares [Member]
Disclosure of detailed information about financial instruments [line items]
Convertible Preferred Shares, Carrying Amount	$ 133,529	0
Preferred shares [member] \| IPO scenario [Member]
Disclosure of detailed information about financial instruments [line items]
Percentage of reasonably possible increase in unobservable input, liabilities	10.00%
Increase (decrease) in fair value measurement due to reasonably possible increase in unobservable input, liabilities		42,900
Increase (decrease) in fair value measurement due to reasonably possible decrease in unobservable input, liabilities		$ 42,000
Currency risk [member]
Disclosure of detailed information about financial instruments [line items]
Percentage of decrease in foreign exchange rate	5.00%
Percentage of decrease increase in Foreign Exchnage Rate	5.00%
Percentage of increase in foreign exchange rate	5.00%

Financial Instruments - Summary of Credit Risk Exposure (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of credit risk exposure [line items]
Financial assets at amortised cost	$ 32,166	$ 39,983
Financial assets	32,166	39,983
12-month ECL [Member] \| Low Risk [Member] \| Deposits [Member]
Disclosure of credit risk exposure [line items]
Financial assets	110	129
12-month ECL [Member] \| A3 [Member] \| Time deposits with maturity less than twelve months [Member]
Disclosure of credit risk exposure [line items]
Financial assets	0	2,872
12-month ECL [Member] \| A3 [Member] \| Time deposits with maturity greater than twelve months [Member]
Disclosure of credit risk exposure [line items]
Financial assets	0	4,307
12-month ECL [Member] \| A3 to Aa2 [Member] \| Cash and cash equivalents [Member]
Disclosure of credit risk exposure [line items]
Financial assets	$ 32,056	$ 32,675

Critical Accounting Judgment and Key Sources of Estimation Uncertainty - Additional Information (Detail) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Disclosure Of Accounting Judgements And Estimates [Line Items]

Financial liabilities at fair value through profit or loss

$ 330

$ 511,861

Fair value change of convertible preferred shares

76,430

189,646

$ 37,424

Intangible assets other than goodwill

14,757

14,778

14,798

Impairment and derecognition of intangible assets

3,000

Patent Rights (not yet available for use) [Member]

Disclosure Of Accounting Judgements And Estimates [Line Items]

Intangible assets other than goodwill

^[1]

14,500

$ 14,500

Convertible Preferred Shares [Member]

Disclosure Of Accounting Judgements And Estimates [Line Items]

Financial liabilities at fair value through profit or loss

$ 0

$ 511,861

[1]

Other Income - Summary of Information about Other Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of Detailed Information about Other Income [Line Items]
Interest income	$ 753	$ 431	$ 467
Government grants (note i)	464	1,016	587
Total	$ 1,217	$ 1,447	$ 1,054

Adoption of New and Amendments to IFRSs - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Financial liabilities at fair value through profit or loss	$ 330	$ 511,861
Right-of-use assets	425	991
Lease liabilities	425	991
Convertible Preferred Shares [Member]
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Financial liabilities at fair value through profit or loss	$ 0	511,861
Convertible Preferred Shares [Member] \| Classification of Liabilities as Current or Non-current [member]
Disclosure of expected impact of initial application of new standards or interpretations [line items]
Financial liabilities at fair value through profit or loss		$ 511,861

Right-Of-Use Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Disclosure of quantitative information about right-of-use assets [line items]
Lease liabilities	$ 425	$ 991
Right-of-use assets	$ 425	$ 991
Bottom of Range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Lease term	12 months
Top of Range [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Lease term	60 months

Financial Instruments - Summary of Categories of Financial Instruments (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Financial assets
Financial assets at FVTPL	$ 5,761	$ 19,067
Amortized cost	32,166	39,983
Financial liabilities
Financial liability at FVTPL	330	511,861
Amortized cost	$ 5,970	$ 7,606

Cover Page - shares	12 Months Ended
Cover Page - shares	Dec. 31, 2023	Dec. 31, 2022	Mar. 28, 2024
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Entity Registrant Name	Apollomics Inc.
Entity Central Index Key	0001944885
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Common Stock, Shares Outstanding			89,495,790
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Title of 12(b) Security	Class A Ordinary Shares, par value $0.0001 per share
Trading Symbol	APLM
Security Exchange Name	NASDAQ
Entity File Number	001-41670
Entity Incorporation, State or Country Code	E9
Entity Address, Address Line One	989 E. Hillsdale Blvd., Suite 220
Entity Address, City or Town	Foster City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94404
Entity Address, Country	US
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Document Accounting Standard	International Financial Reporting Standards
Auditor Name	Grant Thornton LLP	Deloitte Touche Tohmatsu Certified Public Accountants LLP
Auditor Firm ID	248	1113
Auditor Location	San Francisco, California	Shenzhen, the People's Republic of China
Business Contact [Member]
Document Information [Line Items]
Contact Personnel Name	Sanjeev Redkar
Entity Address, Address Line One	989 E. Hillsdale Blvd., Suite 220
Entity Address, City or Town	Foster City
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94404
City Area Code	650
Local Phone Number	209-4055
Warrants [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable to purchase one Class A Ordinary Share at an exercise price of $11.50 per share
Trading Symbol	APLMW
Security Exchange Name	NASDAQ

Major Non-Cash Transactions	12 Months Ended
Major Non-Cash Transactions	Dec. 31, 2023
Major Non-Cash Transactions [Abstract]
Major Non-Cash Transactions	33. MAJOR NON-CASH TRANSACTIONS During the years ended December 31, 2021, 2022 and 2023: (i) the Group entered into new lease agreements for the use of offices and, plant and equipment for 12 months to 60 months. On the lease commencement, the Group recognized $53, $548 and nil of right-of-use asset and lease liabilities, respectively; (ii) financial liabilities arising from unvested restricted shares and treasury shares of $1,605, $1,579 and $68, respectively, have been derecognized upon vesting of restricted shares.

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Non-current assets
Plant and equipment, net	$ 161	$ 485
Right-of-use assets	425	991
Intangible assets	14,757	14,778
Rental deposits	119	124
Time deposits with maturity greater than twelve months		4,307
Total non-current assets	15,462	20,685
Current assets
Deposits, prepayments and deferred expenses	2,108	1,176
Financial assets at FVTPL	5,761	19,067
Time deposits with maturity less than twelve months		2,872
Cash and cash equivalents	32,056	32,675
Total current assets	39,925	55,790
Total assets	55,387	76,475
Current liabilities
Other payables and accruals	9,162	11,675
Short term bank loans	4,236
Financial liabilities arising from unvested restricted shares		68
Lease liabilities, current portion	158	614
Total current liabilities	13,556	12,357
Net current assets	26,369	43,433
Total assets less current liabilities	41,831	64,118
Non-current liabilities
Lease liabilities, noncurrent portion	267	377
Warrant liabilities at FVTPL	330
Convertible preferred shares		511,861
Total non-current liabilities	597	512,238
Net assets (liabilities)	41,234	(448,120)
Equity
Treasury shares		(68)
Reserves	26,716	14,228
Accumulated losses	(646,965)	(474,600)
Total equity (deficit)	41,234	(448,120)
Issued capital [member]
Equity
Share capital	9	41
Total equity (deficit)	9	3
Share premium [member]
Equity
Share premium	661,474	12,279
Total equity (deficit)	$ 661,474	$ 12,317

Business Combination (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about business combination [abstract]

Summary of Common Stock Outstanding

The following table presents the total Apollomics common stock outstanding immediately after the closing of the Business Combination:


	Number of Shares
Exchange of Maxpro Class A common stock for post-closing Apollomics Class A Ordinary Shares		490,025
Exchange of Maxpro Class B common stock for post-closing Apollomics Class A Ordinary Shares		2,587,500
Exchange of Maxpro Class A common stock subject to possible redemption that was not redeemed for post-closing Apollomics Class A Ordinary Shares		79,940
Issuance of post-closing Apollomics Class A Ordinary Shares to Maxpro Sponsor in connection with conversion of a convertible promissory note		155,250
Subtotal - Business Combination, net of redemptions		3,312,715
Issuance of post-closing Apollomics Class B ordinary shares to PIPE Investors		230,000
Conversion of pre-closing Apollomics convertible preferred shares (converted into pre-closing Apollomics ordinary shares prior to the Business Combination) into Post-Closing Apollomics Ordinary Shares		54,420,956
Issuance of Post-Closing Apollomics Ordinary Shares in connection with the Business Combination due to exercise of pre-closing Apollomics stock options prior to the Business Combination		31,240
Total - Post-Closing Apollomics Ordinary Shares outstanding as a result of Business Combination, PIPE Financing, conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares, and issuance of shares upon Closing due to pre-Closing exercise of stock options (note i)		57,994,911

Schedule of Identifiable Net Assets Acquired

The amount of Maxpro’s identifiable net assets acquired at Closing were as follows:


Cash and cash equivalents	$	954
Notes payable – sponsor		(1,999	)
Accrued liabilities		(1,056	)
Deferred underwriting compensation		(3,623	)
Total Maxpro identifiable net liabilities at fair value	$	(5,724	)

Schedule of IFRS 2 Listing Expense

The net assets of Maxpro are stated at fair value with no goodwill or other intangible assets recorded. The IFRS 2 listing expense was calculated as follows:


	Per Share Value (at March 29, 2023)		Shares (in thousands)			Fair Value (in thousands)
Maxpro public stockholders	$	10.81		10,350		$	111,884
Sponsor parties		10.81		3,207			34,668
Underwriter shares		10.81		26			281
Maxpro private warrants		0.12		619			74
Maxpro public warrants		0.12		10,350			1,242
Redemptions of Maxpro class A common stock		10.55		(10,270	)		(108,349	)
				14,282			39,800
Net liabilities of Maxpro							(5,724	)
IFRS 2 Listing Expense						$	45,524

The prior year’s shares and per share numbers have been retrospectively adjusted for the Exchange Ratio of 0.071679.

Consolidated Statements of Changes in Shareholders' Equity Deficit - USD ($)

Total

Share capital [Member]

Treasury shares [Member]

Share premium [Member]

Other reserve [Member]

Share-based payment reserve [Member]

Accumulated losses [Member]

Balance at the beginning (in Shares) (Previously stated [Member]) at Dec. 31, 2020

386,741,005

26,365,915

Balance at the beginning (in Shares) at Dec. 31, 2020

27,721,202

1,889,882

Balance at the beginning (Previously stated [Member]) at Dec. 31, 2020

$ (127,933,000)

$ 39,000

$ (3,252,000)

$ 11,748,000

$ 1,620,000

$ 3,455,000

$ (141,543,000)

Balance at the beginning at Dec. 31, 2020

(127,931,000)

$ 3,000

$ (3,252,000)

11,786,000

1,620,000

3,455,000

(141,543,000)

Recapitalization of Apollomics at Exchange Ratio, (in Shares) (Increase (decrease) due to changes in accounting policy and corrections of prior period errors [Member]) at Dec. 31, 2020

(359,019,803)

(24,476,033)

Recapitalization of Apollomics at Exchange Ratio (Increase (decrease) due to changes in accounting policy and corrections of prior period errors [Member]) at Dec. 31, 2020

2,000

$ (36,000)

38,000

Loss and total comprehensive loss for the year, attributable to owners of the Company

(94,797,000)

Exercise of share options (in Shares)

^[1]

466,712

Forfeiture of vested share options

^[1]

140,000

51,000

(51,000)

(905,000)

905,000

Restricted share awards vested (in Shares)

^[2]

(455,356)

Restricted share awards vested

^[2]

64,000

$ 64,000

63,000

(63,000)

Early exercised share options vested during the year (in Shares)

(424,802)

Early exercised share options vested during the year

1,541

$ 1,541

706

(706)

Recognition of equity-settled share-based payment

8,122

Balance at the ending (in Shares) at Dec. 31, 2021

28,187,914

1,009,724

Balance at the ending at Dec. 31, 2021

(212,861,000)

$ 3,000

$ (1,647,000)

11,926,000

2,440,000

9,852,000

(235,435,000)

Loss and total comprehensive loss for the year, attributable to owners of the Company

(240,811,000)

Exercise of share options (in Shares)

^[3]

613,012

Forfeiture of vested share options

^[3]

391,000

205,000

(205,000)

(1,646,000)

1,646,000

Restricted share awards vested (in Shares)

^[2]

(83,482)

Restricted share awards vested

^[2]

21,000

$ 21,000

39,000

(39,000)

Early exercised share options vested during the year (in Shares)

(429,490)

Early exercised share options vested during the year

1,558,000

$ 1,558,000

714,000

(714,000)

Recognition of equity-settled share-based payment

3,582,000

Balance at the ending (in Shares) at Dec. 31, 2022

28,800,926

496,752

Balance at the ending at Dec. 31, 2022

(448,120,000)

$ 3,000

$ (68,000)

12,317,000

3,398,000

10,830,000

(474,600,000)

Loss and total comprehensive loss for the year, attributable to owners of the Company

(172,601,000)

Exercise of share options (in Shares)

^[4]

62,443

Forfeiture of vested share options

^[4]

85,000

33,000

(33,000)

(198,000)

198,000

Restricted share awards vested (in Shares)

^[2]

(496,752)

Restricted share awards vested

^[2]

68,000

$ 68,000

4,000

(4,000)

Business combination, net of redemptions (in Shares)

3,312,715

Business combination, net of redemptions

$ 757,000

Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares (in Shares)

588,291,000

54,420,956

588,285,000

Conversion of pre-closing Apollomics convertible preferred shares into Post-Closing Apollomics Ordinary Shares

$ 6,000

IFRS 2 listing expense

$ 45,524,000

Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs (in Shares)

230,000

Post-closing Apollomics Class B Ordinary Shares issued to PIPE Investors, net of transaction costs

261,000

Reclassification from equity to non-current liabilities for maxpro warrants assumed by apollomics upon Closing

^[4]

(7,105,000)

Issuance of post-closing Apollomics Class A ordinary shares upon the conversion of post-closing Apollomics Series A Preferred Shares (in Shares)

2,668,750

Issuance of post-closing Apollomics Class A ordinary shares upon the conversion of post-closing Apollomics Series A Preferred Shares

21,350,000

Recognition of equity-settled share-based payment

12,686,000

Portion of PIPE issuance costs allocated to PIPE warrants

38,000

Balance at the ending (in Shares) at Dec. 31, 2023

89,495,790

Balance at the ending at Dec. 31, 2023

$ 41,234,000

$ 9,000

$ 661,474,000

$ 3,435,000

$ 23,281,000

$ (646,965,000)

[1]	The total number of shares issued from the exercise of stock options consisted of the issuance of 6,511,135 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2021 to December 31, 2021. These Pre-Closing Apollomics Ordinary Shares were exchanged for 466,712 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination.
[2]	All unvested restricted shares were milestone-based restricted shares held by the Chief Executive Officer of Apollomics which vested upon the Closing of the Business Combination.
[3]	The total number of shares issued from the exercise of stock options consisted of the issuance of 8,552,187 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2022 to December 31, 2022. These Pre-Closing Apollomics Ordinary Shares were exchanged for 613,012 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination.
[4]	The total number of shares issued from the exercise of stock options consisted of the issuance of 435,833 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2023 to March 28, 2023. These Pre-Closing Apollomics Ordinary Shares were exchanged for 31,241 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 31,202 Post-Closing Apollomics Ordinary Shares between March 29, 2023 to December 31, 2023, totaling 62,443 exercise of stock options for the year ended December 31, 2023.

Short Term Bank Loans - Additional Information (Detail) $ in Thousands, ¥ in Millions	6 Months Ended		8 Months Ended
	May 31, 2024 CNY (¥)	May 31, 2024 USD ($)	Jul. 31, 2024 CNY (¥)	Jul. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Nov. 30, 2023 CNY (¥)	Nov. 30, 2023 USD ($)
Disclosure of detailed information about borrowings [line items]
Short term bank loans					$ 4,236
Line Of Credit
Disclosure of detailed information about borrowings [line items]
Short term bank loans						¥ 80	$ 11,200
Line Of Credit 1
Disclosure of detailed information about borrowings [line items]
Short term bank loans						¥ 50	$ 7,000
Drew down Amount			¥ 20	$ 2,800
Interest Rate						3.70%	3.70%
Line Of Credit 2
Disclosure of detailed information about borrowings [line items]
Short term bank loans						¥ 30	$ 4,200
Drew down Amount	¥ 10	$ 1,400
Interest Rate						3.20%	3.20%

Business Combination - Schedule of Common Stock Outstanding (Parenthetical) (Detail)

1 Months Ended

12 Months Ended

Nov. 30, 2023

May 31, 2023

Apr. 30, 2023

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Mar. 29, 2023

Dec. 31, 2020

PIPE Financing and Business Combination [Member]

Disclosure of detailed information about business combination [line items]

Disclosure of detailed information about business combination [line items]

57,994,911

Share capital [Member]

89,495,790

28,800,926

28,187,914

27,721,202

Disclosure of detailed information about business combination [line items]

62,443

^[1]

613,012

^[2]

466,712

^[3]

Ordinary Shares [Member]

401,804,327

Post-Closing Apollomics Ordinary Shares [Member]

15,000

Disclosure of detailed information about business combination [line items]

28,800,926

Conversion of convertible preferred A stock into common stock

16,202

2,668,750

Conversion ratio for conversion of preferred stock into common stock

1.25

[1]	The total number of shares issued from the exercise of stock options consisted of the issuance of 435,833 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2023 to March 28, 2023. These Pre-Closing Apollomics Ordinary Shares were exchanged for 31,241 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination. The total number of shares issued from the exercise of stock options consisted of the issuance of 31,202 Post-Closing Apollomics Ordinary Shares between March 29, 2023 to December 31, 2023, totaling 62,443 exercise of stock options for the year ended December 31, 2023.
[2]	The total number of shares issued from the exercise of stock options consisted of the issuance of 8,552,187 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2022 to December 31, 2022. These Pre-Closing Apollomics Ordinary Shares were exchanged for 613,012 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination.
[3]	The total number of shares issued from the exercise of stock options consisted of the issuance of 6,511,135 Pre-Closing Apollomics Ordinary Shares from stock options exercised between January 1, 2021 to December 31, 2021. These Pre-Closing Apollomics Ordinary Shares were exchanged for 466,712 Post-Closing Apollomics Ordinary Shares, in accordance with the Exchange Ratio upon the Closing of the Business Combination.

Income Tax Expenses - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure Of Detailed Information About Income Tax [Line Items]
Tax expense (income)	$ 10,000	$ 1,000	$ 1,000
Accounting profit	$ (172,591,000)	$ (240,810,000)	$ (94,796,000)
Apollomics Australia Pty Ltd [Member]
Disclosure Of Detailed Information About Income Tax [Line Items]
Applicable tax rate	25.00%	25.00%	26.00%
UNITED STATES \| Federal Income Tax Rate [Member]
Disclosure Of Detailed Information About Income Tax [Line Items]
Applicable tax rate	21.00%
CHINA
Disclosure Of Detailed Information About Income Tax [Line Items]
Applicable tax rate	25.00%	25.00%	25.00%
HONG KONG
Disclosure Of Detailed Information About Income Tax [Line Items]
Applicable tax rate	16.50%
Tax expense (income)	$ 0	$ 0	$ 0
Accounting profit	$ 0	$ 0	$ 0

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

Summary of Detailed Information about Loss After Charging Expenses

Loss for the Year (Tables)

12 Months Ended

Dec. 31, 2023

Profit (loss) [abstract]


	Years ended December 31,
	2021		2022		2023
Loss for the year has been arrived at after charging:
Staff costs:
Salaries and other allowances	$	18,871	$	14,966	$	10,356
Retirement benefits scheme contributions		749		662		499
Share-based payment expenses		8,122		3,582		12,685
Total staff costs		27,742		19,210		23,540
Depreciation of plant and equipment		133		162		87
Depreciation of right-of-use assets		528		593		587
Amortization of intangible assets		20		20		20
Impairment loss of an intangible asset		3,000		—		—
Other expense (note)	$	4,522	$	6,608	$	46,003

Business Combination - Additional Information (Detail)			1 Months Ended
Business Combination - Additional Information (Detail)	Mar. 29, 2023 USD ($) $ / shares shares	Mar. 28, 2023 USD ($) shares	Nov. 30, 2023 shares	Apr. 30, 2023 shares	Dec. 31, 2022 shares
Disclosure of detailed information about business combination [line items]
Promissory note payable principal balance \| $		$ 1,500,000
One-time share-based expense on business combination \| $	$ 45,500,000
Other intangible assets \| $	$ 0
Class A Common Stock [Member]
Disclosure of detailed information about business combination [line items]
Exercise of share options		435,833
Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding					28,800,926
Exercise of share options				16,202
Common Stock Shares Issued In Exchange Of Ordinary Shares Held In The Previous Company [Member] \| Class A Common Stock [Member]
Disclosure of detailed information about business combination [line items]
Common stock shares conversion ratio for each share held in the previous company	1
Common Stock Shares Issued In Exchange Of Ordinary Shares Held In The Previous Company [Member] \| Class B Common Stock [Member]
Disclosure of detailed information about business combination [line items]
Common stock shares conversion ratio for each share held in the previous company	1
PIPE Financing and Business Combination [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	57,994,911
Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	401,804,327
Exercise of share options			15,000
Ordinary Shares [Member] \| Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares issued and fully paid exchange ratio pursuant to business combination	0.071679
Class A ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares issued	28,800,926
Number of warrants entitled for each share purchased	57,500
Class A ordinary Shares [Member] \| Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares issued and fully paid exchange ratio pursuant to business combination	0.071679
Number of shares issued	31,240
Class A ordinary Shares [Member] \| Pipe Subscription Agreement [Member]
Disclosure of detailed information about business combination [line items]
Gross proceeds from issuance of shares \| $	$ 23,700,000
Class of warrant or rights number of shares to be issued on exercise of each warrant	1
Class B ordinary Shares [Member] \| Pipe Subscription Agreement [Member]
Disclosure of detailed information about business combination [line items]
Increase (decrease) in number of ordinary shares issued	230,000
Share issued price \| $ / shares	$ 10
Series A Preferred Shares [Member] \| Pipe Subscription Agreement [Member]
Disclosure of detailed information about business combination [line items]
Increase (decrease) in number of ordinary shares issued	2,135,000
Share issued price \| $ / shares	$ 10
Maxpro Capital Acquisition Corp. [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	10,350,000
Number of shares redeemed	10,270,060
Percentage of redemption of shares in connection with public shares available	99.20%
Maxpro Capital Acquisition Corp. [Member] \| Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	54,420,956
Maxpro Capital Acquisition Corp. [Member] \| Pipe Subscription Agreement [Member]
Disclosure of detailed information about business combination [line items]
Proceeds from financing and business combination \| $	$ 20,200,000
Maxpro Capital Acquisition Corp. [Member] \| PIPE Financing and Business Combination [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	57,994,911
Maxpro Capital Acquisition Corp. [Member] \| Private Warrants [Member]
Disclosure of detailed information about business combination [line items]
Class of warrants or rights outstanding	464,150
Unpaid principal amount converted into shares	155,250
Maxpro Capital Acquisition Corp. [Member] \| Public Warrants [Member]
Disclosure of detailed information about business combination [line items]
Class of warrants or rights outstanding	10,350,000
Maxpro Capital Acquisition Corp. [Member] \| Class A ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Unpaid principal amount converted into shares	155,250
Maxpro Capital Acquisition Corp. [Member] \| Class A ordinary Shares [Member] \| Class A Common Stock [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	490,025
Maxpro Capital Acquisition Corp. [Member] \| Class A ordinary Shares [Member] \| Class B Common Stock [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	2,587,500
Maxpro Capital Acquisition Corp. [Member] \| Class A ordinary Shares [Member] \| Post-Closing Apollomics Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	31,240
Maxpro Capital Acquisition Corp. [Member] \| Class B ordinary Shares [Member] \| Pipe Subscription Agreement [Member]
Disclosure of detailed information about business combination [line items]
Number of shares outstanding	230,000

Critical Accounting Judgment and Key Sources of Estimation Uncertainty

12 Months Ended

Dec. 31, 2023

Disclosure of Accounting Judgements and Estimates [Abstract]

Critical Accounting Judgment and Key Sources of Estimation Uncertainty

CRITICAL ACCOUNTING JUDGMENT AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the Group’s accounting policies, which are described in Note 4, the management of the Company are required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Critical judgment in applying accounting policies

The following is the critical judgment, apart from those involving estimations (see below), that the Company have made in the process of applying the Group’s accounting policies and that have the most significant effect on the amounts recognized in the consolidated financial statements.

Research and development expenses

Development costs incurred on the Group’s research and development projects are capitalized and deferred only when the Group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use or sale, the Group’s intention to complete and the Group’s ability to use or sell the asset, how the asset will generate future economic benefits, the availability of resources to complete the pipeline and the ability to measure reliably the expenditure during the development. Development costs which do not meet these criteria are expensed when incurred.

The Company assesses the progress of each of the research and development projects and determines whether the criteria are met for capitalization. During the years ended December 31, 2021, 2022 and 2023, all the related development costs are expensed when incurred.

Key sources of estimation uncertainty

The key assumptions concerning the future, and other key sources of estimation uncertainty at the end of each reporting period, that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the coming twelve months, are described below.

Fair value of convertible preferred shares

The convertible preferred shares of the Company are measured at fair value for financial reporting purpose. No quoted prices in an active market are available for these financial liabilities. These financial liabilities were valued by the management with reference to valuations carried out by an independent qualified professional valuer not connected with the Group, which has appropriate qualifications and experience in valuation of similar financial instruments. The fair value of these financial liabilities is established by using valuation techniques as disclosed in Note 24. Valuation techniques are certified by the valuer before being implemented for valuation and are calibrated to ensure that outputs reflect market conditions. Valuation models established by the valuer make the maximum use of market inputs and rely as little as possible on the Group’s specific data. However, it should be noted that some inputs, such as the underlying share value of the Company, possibilities under different scenarios such as initial public offerings (“IPO”) and time to liquidation require management estimates. The estimates and assumptions by the management of the Company are reviewed periodically and are adjusted if necessary. Should any of the estimates and assumptions change, it may lead to a change in the fair value of the financial liabilities at FVTPL. The fair values of the convertible preferred shares which are classified as financial liabilities at FVTPL as at December 31, 2022 and 2023 were $511,861 and nil, respectively. Upon the IPO, all the pre-closing Apollomics convertible preferred shares converted into Post- Closing Apollomics Ordinary Shares. The fair value loss recognized in the profit or loss during the years ended December 31, 2021, 2022 and 2023 amounted to $37,424, $189,646 and $76,430, respectively.

Estimated impairment of intangible assets not ready for use

Intangible assets not ready for use are tested annually for impairment, or more frequently, if events or changes in circumstances indicate that they might be impaired. The Group obtained in-licenses through separate acquisition to continue research and development work and commercialize the products, which are classified as intangible assets not ready for use.

Determining whether intangible assets not ready for use is impaired requires an estimation of recoverable amount of the cash-generating unit to which the intangible assets belong, which is the higher of the value in use or fair value less costs of disposal. The value in use calculation requires the Group to estimate the future cash flows expected to arising from the cash-generating unit and a suitable discount rate in order to calculate the present value. Where the actual future cash flows are less than expected, or change in facts and circumstances which results in downward revision of future cash flows or upward revision of discount rate, a material impairment loss or further loss may arise.

The carrying amount of intangible assets not ready for use as at December 31, 2022 and 2023, were $14,500. The impairment loss recognized during the years ended December 31, 2021, 2022 and 2023 amounted to $3,000, nil, and nil, respectively.

Deferred Taxation - Disclosure of Detailed Information about Unrecognized Tax Losses Explanatory (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liability (asset)	$ 0	$ 0	$ 0
(Charge) credit to profit or loss	0	(0)	0
Deferred tax liability (asset)	0	0	0
Accelerated Tax Depreciation [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liability (asset)	(51)	(32)	(46)
(Charge) credit to profit or loss	40	(19)	14
Deferred tax liability (asset)	(11)	(51)	(32)
Accrual [Member]
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deferred tax liability (asset)	51	32	46
(Charge) credit to profit or loss	(40)	19	(14)
Deferred tax liability (asset)	$ 11	$ 51	$ 32

Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of detailed information about property, plant and equipment [line items]

Summary of Property, Plant and Equipment


	Leasehold improvements			Furniture and other equipment			Total
COST
As of January 1, 2022	$	135		$	426		$	561
Additions		—			367			367
As of December 31, 2022		135			793			928
Additions		—			—			—
Disposals		—			(363	)		(363	)
As of December 31, 2023		135			430			565
ACCUMULATED DEPRECIATION
As of January 1, 2022		(80	)		(201	)		(281	)
Provided for the year		(34	)		(128	)		(162	)
As of December 31, 2022		(114	)		(329	)		(443	)
Accumulated depreciation removal for disposals		—			75			75
Provided for the year		(18	)		(18	)		(36	)
As of December 31, 2023		(132	)		(272	)		(404	)
CARRYING VALUES
As of December 31, 2022	$	21		$	464		$	485
As of December 31, 2023	$	3		$	158		$	161

Summary of Depreciation Rates of Property Plant and Equipment


Leasehold improvements		Over the shorter of the relevant lease term or 20%
Furniture and other equipment		14% - 33%

General Information - Summary of Information about Consolidated Financial Statements and Company Principal Subsidiaries (Detail)	12 Months Ended
	Dec. 31, 2023
Apollomics Inc [Member]
Disclosure of subsidiaries [line items]
Name of subsidiaries	Apollomics, Inc.
Country of incorporation	California, United States
Date of incorporation	Jan. 14, 2016
Principal activities	Research and development of drugs
Apollomics Australia Pty Ltd [Member]
Disclosure of subsidiaries [line items]
Name of subsidiaries	Apollomics (Australia) Pty. Ltd.
Country of incorporation	Melbourne, Australia
Date of incorporation	Nov. 04, 2016
Principal activities	Research and development of drugs
Apollomics Hong Kong Limited [Member]
Disclosure of subsidiaries [line items]
Name of subsidiaries	Apollomics (Hong Kong) Limited
Country of incorporation	Hong Kong, China
Date of incorporation	Jun. 24, 2019
Principal activities	Investment holding
Zhejiang Crownmab Biotech Co Ltd [Member]
Disclosure of subsidiaries [line items]
Name of subsidiaries	Zhejiang Crownmab Biotech Co., Ltd.
Country of incorporation	Hangzhou, China
Date of incorporation	May 29, 2018
Principal activities	Investment holding and research and development of drugs
Zhejiang Crown Bochuang Biopharma Co Ltd [Member]
Disclosure of subsidiaries [line items]
Name of subsidiaries	Zhejiang Crown Bochuang Biopharma Co., Ltd.
Country of incorporation	Hangzhou, China
Date of incorporation	May 29, 2020
Principal activities	Research and development of drugs
Project Max SPAC Merger Sub Inc [Member]
Disclosure of subsidiaries [line items]
Name of subsidiaries	Project Max SPAC Merger Sub, Inc.
Country of incorporation	Delaware, United States
Date of incorporation	Aug. 19, 2022
Principal activities	Investment holding

Loss for the Year - Summary of Detailed Information about Loss After Charging Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Staff costs:
Salaries and other allowances	$ 10,356	$ 14,966	$ 18,871
Retirement benefits scheme contributions	499	662	749
Share-based payment expenses	12,685	3,582	8,122
Total staff costs	23,540	19,210	27,742
Depreciation of plant and equipment	87	162	133
Depreciation of right-of-use assets	587	593	528
Amortization of intangible assets	20	20	20
Impairment loss of an intangible asset	0	0	3,000
Other expense	$ 46,003	$ 6,608	$ 4,522

Lease Liabilities - Additional Information (Detail)	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Lease Liabilities [Line Items]
Weighted average lessee's incremental borrowing rate	4.85%	5.38%
Top of Range [Member]
Disclosure of Lease Liabilities [Line Items]
Weighted average lessee's incremental borrowing rate	6.00%	6.00%
Bottom of Range [Member]
Disclosure of Lease Liabilities [Line Items]
Weighted average lessee's incremental borrowing rate	4.75%	4.75%

Finance Costs

12 Months Ended

Dec. 31, 2023

Disclosure of Finance Cost [Abstract]

Finance Costs

10.

FINANCE COSTS


	Years ended December 31,
	2021		2022		2023
Interest expenses on lease liabilities	$	83	$	93	$	150

Other Payables and Accruals (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure Of Other Payables And Accruals [Abstract]

Summary of Other Payables And Accruals


	As of December 31,
	2022		2023
Payables in respect of research and development expenses	$	5,435	$	4,471
Accrued salaries and bonuses		2,475		2,166
Accrued other expenses		1,662		1,025
Deposit received for a potential out-licensing drug patent (note)		1,000		1,000
Other payables		1,103		500
	$	11,675	$	9,162

Schedule I - Condensed Statements of Financial Position (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2021	Dec. 31, 2020
Non-current assets
Intangible assets	$ 14,757	$ 14,778	$ 14,798
Total non-current assets	15,462	20,685
Current assets
Deposits, prepayments and deferred expenses	2,108	1,176
Financial assets at FVTPL	5,761	19,067
Cash and cash equivalents	32,056	32,675	46,740		$ 130,645
Total current assets	39,925	55,790
Total assets	55,387	76,475
Current liabilities
Other payables and accruals	9,162	11,675
Financial liabilities arising from unvested restricted shares		68
Total current liabilities	13,556	12,357
Net current assets	26,369	43,433
Total assets less current liabilities	41,831	64,118
Non-current liabilities
Convertible preferred shares		511,861
Warrant liabilities	330
Total non-current liabilities	597	512,238
Net assets (liabilities)	41,234	(448,120)
Equity
Treasury shares		(68)	(1,647)	$ (3,252)
Reserves	26,716	14,228
Accumulated losses	(646,965)	(474,600)
Total equity (deficit)	41,234	(448,120)	(212,861)		(127,931)
Separate [Member]
Non-current assets
Intangible assets	1,759	1,778
Amount due from subsidiaries	70,103	70,560
Total non-current assets	71,862	72,338
Current assets
Deposits, prepayments and deferred expenses	630
Financial assets at FVTPL	5,761	19,067
Cash and cash equivalents	2,330	6,001	$ 32,861		$ 73,621
Total current assets	8,721	25,068
Total assets	80,583	97,406
Current liabilities
Other payables and accruals	366	2,986
Financial liabilities arising from unvested restricted shares		68
Total current liabilities	366	3,054
Net current assets	8,355	22,014
Total assets less current liabilities	80,217	94,352
Non-current liabilities
Convertible preferred shares		511,861
Warrant liabilities	330
Deficit in subsidiaries	38,653	30,611
Total non-current liabilities	38,983	542,472
Net assets (liabilities)	41,234	(448,120)
Equity
Share capital	9	41
Treasury shares		(68)
Share premium	661,474	12,279
Reserves	26,716	14,228
Accumulated losses	(646,965)	(474,600)
Total equity (deficit)	$ 41,234	$ (448,120)

Share-Based Payment Transactions (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Summary of Group's Restricted Shares Movement

The following table summarized the Group’s restricted shares movement during the years ended December 31, 2021, 2022 and 2023:


	2021			2022			2023
	Number of unvested restricted shares			Number of unvested restricted shares			Number of unvested restricted shares
Outstanding at January 1,		14,447,616			8,094,901			6,930,235
Vested		(6,352,715	)		(1,164,666	)		(6,930,235	)
Outstanding at December 31,		8,094,901			6,930,235			—

To present these restricted shares to give effect to the Business Combination of March 29, 2023 at the exchange ratio of 0.071679, these would have been presented as follows:


	2021			2022			2023
	Number of unvested restricted shares			Number of unvested restricted shares			Number of unvested restricted shares
Outstanding at January 1,		1,889,882			1,009,724			496,752
Vested		(880,158	)		(512,972	)		(496,752	)
Outstanding at December 31,		1,009,724			496,752			—

Summary of Company's Share Options

The following table discloses movements of the Company’s share options under the 2016 Plan held by grantees during the years ended December 31, 2021 and 2022:


	2021					2022
	Number of Options			Weighted- average exercise price		Number of Options			Weighted- average exercise price
Outstanding at January 1,		151,133,235		$	0.169		155,059,183		$	0.203
Granted		39,715,000		0.279			11,500,000			0.310
Exercised		(6,511,135	)	0.022			(8,552,187	)	0.046
Forfeited		(29,277,917	)	0.169			(22,027,291	)	0.232
Outstanding at December 31,		155,059,183		0.203			135,979,705		0.217
Exercisable at the end of the year		78,269,054					67,667,737


	2021					2022					2023
	Number of Options			Weighted- average exercise price		Number of Options			Weighted- average exercise price		Number of Options			Weighted- average exercise price
Outstanding at January 1,		10,833,079		$	2.358		11,114,486		$	2.832		9,746,889		$	3.027
Options granted		2,846,731		3.892			824,309			4.325		3,048,310			9.927
Exercised		(466,712	)	0.307			(613,012	)	0.642			(62,443	)	1.397
Forfeited		(2,098,612	)	2.238			(1,578,894	)	3.237			(808,341	)		0.570
Outstanding at December 31,		11,114,486		2.832			9,746,889		3.027			11,924,415		4.615
Exercisable at the end of the year		5,610,248					4,850,356					7,859,478

Summary of Share-Based Payment Transactions

The key inputs into the model were as follows:


	Years ended December
	2021			2022			2023
Grant date option fair value per share	$0.1430-0.1544			$0.0933-0.1517			$0.01-0.511
Exercise price	$0.26-0.31			$0.31			$0.07-0.72
Grant date option fair value per share as converted	$1.995-2.154			$1.302-2.116			$0.14-7.127
Exercise price as converted	$3.63-4.32			$4.32			$0.94-10.01
Expected volatility (note i)	75%-80%			75%-77.5%				72.5	%
Expected life	6.078 years			6.078 years			6.250 years
Risk-free rate	0.51%-1.09%			1.35%-3.98%				3.67	%
Expected dividend yield		—	%		—	%		—	%

Note: The expected volatility measured at the standard deviation is based on the historical data of the daily share price movement of comparable companies.

Summary of Restricted stock


	Year ended December 31, 2023
	Number of restricted stocks		Weighted- average exercise price
Outstanding at January 1, 2023		—	$	—
Restricted stock granted		207,945	$	5.410
Outstanding at December 31, 2023		207,945	$	5.410
Exercisable at the end of the year		—

Financial Instruments - Summary of Assets and Liabilities Denominated in Foreign Currencies (Detail) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items]
Assets	$ 32,166	$ 39,983
Foreign Currency Denominated Market Risk [Member]
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items]
Assets	6,867	10,240
Liabilities	6,214	2,659
Renminbi ("RMB") \| Foreign Currency Denominated Market Risk [Member]
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items]
Assets	6,071	8,940
Liabilities	5,443	1,210
Australian Dollars ("AUD") [Member] \| Foreign Currency Denominated Market Risk [Member]
Disclosure of Detailed Information about Assets and Liabilities Denominated in Foreign Currencies [Line Items]
Assets	796	1,300
Liabilities	$ 771	$ 1,449

The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

Short Term Bank Loans	12 Months Ended
Short Term Bank Loans	Dec. 31, 2023
Disclosure of detailed information about borrowings [abstract]
Short Term Bank Loans	20. SHORT TERM BANK LOANS In November 2023 we established two lines of credit totaling RMB 80 million (approximately $11.2 million) with two banks in China. Against one line of credit of RMB 50 million (approximately $7.0 million) we drew down RMB 20 million (approximately $2.8 million) for 8 months due July 2024 at 3.7% interest. Against the second bank’s line of credit of RMB 30 million (approximately $4.2 million) we drew down RMB 10 million (approximately $1.4 million) for 6 months due May 2024 at 3.2% interest.

Income Tax Expenses - Summary of Information about Components of Tax Expense Income (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Major components of tax expense (income) [abstract]
current year	$ 10,000	$ 1,000	$ 1,000
over-provision in respect of prior years	0	0	0
Deferred tax	0	0	0
Tax expense (income)	$ 10,000	$ 1,000	$ 1,000

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]